Research reference only. Not medical advice. Most compounds are not FDA-approved. These are research chemicals, not for human consumption. Consult a qualified clinician.Read methodology Terms update on 18 Dec 2026
← Back to Research Index
Compare Evaluate Matrix Half-Life
Dossier · № 24 of 110 Updated Nov 17, 2026

SS-31

Elamipretide · Bendavia · MTP-131

PHASE 3 (NOT APPROVED) · MITOCHONDRIA-TARGETED TETRAPEPTIDE

▓ 206 indexed citations across PubMed (156), ClinicalTrials.gov (1), EuropePMC (49).

Citation breakdown by evidence tier

← weaker evidence  ·  stronger evidence →

206 citations across 7 tiers

Tap any tier to jump to that section of the bibliography.

Mechanism of action

Binds cardiolipin on inner mitochondrial membrane; preserves electron transport chain function

Researched effects

Mitochondrial function; cardiolipin protection; FDA accelerated approval (FORZINITY, 2025) to improve muscle strength in Barth syndrome, based on knee extensor strength as an intermediate endpoint 1516; primary mitochondrial myopathy (Phase 3 mixed) 2

Reported efficacy (trial readout)

  • Mitochondrial Function 96.1 meters (6MWT cumulative)

    TAZPOWER OLE elamipretid (168wk)

    Medium confidence

Trial-efficacy data current as of November 16, 2026.

Live evidence

FDA label safety

Contraindications

4 CONTRAINDICATIONS Serious hypersensitivity to elamipretide or any of the excipients in FORZINITY [see Warnings and Precautions (5.2) ]. Serious hypersensitivity to any of the ingredients ( 4 , 5.2 )

Full FDA label (DailyMed) →

Recent literature

Live signals refreshed daily. Current as of November 19, 2026.

Dosing reported in literature

40 mg SC once daily (FORZINITY label, patients weighing at least 30 kg; reduced in severe renal impairment) 15

Known concerns

Injection site reactions (most common in the label); skin rash/urticaria; contains benzyl alcohol, not approved for neonates 15; FDA complete response letter (2023) for primary mitochondrial myopathy

Top-ranked picks

10 pre-curated authoritative sources, ranked by journal tier and study weight.

  1. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial.

    Neurology · 2023 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 78.3

  2. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy.

    Neurology · 2018 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 77.8

  3. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial.

    Orphanet journal of rare diseases · 2024 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.4

  4. Long-term efficacy and safety of elamipretide in patients with Barth syndrome: 168-week open-label extension results of TAZPOWER.

    Genetics in medicine : official journal of the American College of Medical Genetics · 2024 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.4

  5. Elamipretide Topical Ophthalmic Solution for the Treatment of Subjects with Leber Hereditary Optic Neuropathy: A Randomized Trial.

    Ophthalmology · 2024 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.4

  6. Identifying responders to elamipretide in Barth syndrome: Hierarchical clustering for time series data.

    Orphanet journal of rare diseases · 2023 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.3

  7. A randomized crossover trial of elamipretide in adults with primary mitochondrial myopathy.

    Journal of cachexia, sarcopenia and muscle · 2020 — RANDOMISED CONTROLLED TRIALS · AUTHORITY 74.0

  8. FRDA Investigator Initiated Study (IIS) With Elamipretide

    2022 — TRIAL REGISTRATIONS (CLINICALTRIALS.GOV) · AUTHORITY 73.2

  9. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome.

    Orphanet journal of rare diseases · 2022 — CLINICAL TRIALS · AUTHORITY 69.2

  10. Elamipretide: First Approval.

    Drugs · 2026 — REVIEWS · AUTHORITY 54.5

Full citation library

Year distribution

Randomised Controlled Trials

7
  1. 1.

    Karaa A, Bertini E, Carelli V, Cohen BH, et al. · Neurology · 2023 · PMID 37268435

    Primary mitochondrial myopathies (PMMs) encompass a group of genetic disorders that impair mitochondrial oxidative phosphorylation, adversely affecting physical function, exercise capacity, and quality of life (QoL). Current PMM standards of care address symptoms, with limited clinical impact, constituting a significant therapeutic unmet need. We present data from MMPOWER-3, a pivotal, phase-3, randomized, double-blind, placebo-controlled clinical trial that evaluated the efficacy and safety of…

  2. 2.

    Karaa A, Bertini E, Carelli V, Cohen B, et al. · Orphanet journal of rare diseases · 2024 · PMID 39574155

    As previously published, the MMPOWER-3 clinical trial did not demonstrate a significant benefit of elamipretide treatment in a genotypically diverse population of adults with primary mitochondrial myopathy (PMM). However, the prespecified subgroup of subjects with disease-causing nuclear DNA (nDNA) pathogenic variants receiving elamipretide experienced an improvement in the six-minute walk test (6MWT), while the cohort of subjects with mitochondrial DNA (mtDNA) pathogenic variants showed no diff…

  3. 3.

    Thompson WR, Manuel R, Abbruscato A, Carr J, et al. · Genetics in medicine : official journal of the American College of Medical Genetics · 2024 · PMID 38602181

    Evaluate long-term efficacy and safety of elamipretide during the open-label extension (OLE) of the TAZPOWER trial in individuals with Barth syndrome (BTHS). TAZPOWER was a 28-week randomized, double-blind, and placebo-controlled trial followed by a 168-week OLE. Patients entering the OLE continued elamipretide 40 mg subcutaneous daily. OLE primary endpoints were safety and tolerability; secondary endpoints included change from baseline in the 6-minute walk test (6MWT) and BarTH Syndrome Symptom…

  4. 4.

    Karanjia R, Sadun AA · Ophthalmology · 2024 · PMID 37923251

    This study aimed to assess the safety, tolerability, and potential efficacy of topical elamipretide in patients affected with Leber hereditary optic neuropathy (LHON). This phase II, prospective, randomized, vehicle-controlled, single-center clinical trial involved administration of elamipretide 1% topical ophthalmic solution to patients with LHON over a 52-week double-masked treatment period, followed by an open-label extension (OLE) for up to 108 additional weeks of treatment. Twelve patients…

  5. 5.

    Van den Eynde J, Chinni B, Vernon H, Thompson WR, et al. · Orphanet journal of rare diseases · 2023 · PMID 37041653

    Barth syndrome (BTHS) is a rare genetic disease that is characterized by cardiomyopathy, skeletal myopathy, neutropenia, and growth abnormalities and often leads to death in childhood. Recently, elamipretide has been tested as a potential first disease-modifying drug. This study aimed to identify patients with BTHS who may respond to elamipretide, based on continuous physiological measurements acquired through wearable devices. Data from a randomized, double-blind, placebo-controlled crossover t…

  6. 6.

    Karaa A, Haas R, Goldstein A, Vockley J, et al. · Neurology · 2018 · PMID 29500292

    To assess the safety and efficacy of elamipretide, an aromatic-cationic tetrapeptide that readily penetrates cell membranes and transiently localizes to the inner mitochondrial membrane where it associates with cardiolipin, in adults with primary mitochondrial myopathy (PMM). A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 for the Treatment of Mitochondrial Myopathy (MMPOWER) was a phase I/II multicenter, randomized, double-blind, placebo-controlled trial of elamipretide…

  7. 7.

    Karaa A, Haas R, Goldstein A, Vockley J, et al. · Journal of cachexia, sarcopenia and muscle · 2020 · PMID 32096613

    This study aims to evaluate the effect of subcutaneous (SC) elamipretide dosing on exercise performance using the 6 min walk test (6MWT), patient-reported outcomes measuring fatigue, functional assessments, and safety to guide the development of the Phase 3 trial. MMPOWER-2 was a randomized, double-blind, placebo-controlled, crossover trial that enrolled participants (N = 30) with genetically confirmed primary mitochondrial myopathy. Participants were randomly assigned (1:1) to 40 mg/day SC elam…

Clinical Trials

1
  1. 8.

    Hornby B, Thompson WR, Almuqbil M, Manuel R, et al. · Orphanet journal of rare diseases · 2022 · PMID 36056411

    Natural history studies are increasingly recognized as having an important role in drug development for rare diseases. A phase 3, observational, retrospective, and non-interventional study was designed to establish a natural history control (NHC) cohort of patients with Barth syndrome (BTHS) to provide further analysis of the efficacy of elamipretide observed in an open-label extension (OLE) phase of the TAZPOWER trial, a clinical trial that tested the efficacy of 40 mg daily of elamipretide in…

Trial Registrations (ClinicalTrials.gov)

1
  1. 9.

    NCT05168774 · Phase 1/Phase 2 · Completed · 2022

    Conditions: Friedreich Ataxia

Reviews

40
  1. 10.

    Tung C, Varzideh F, Farroni E, Mone P, et al. · International journal of molecular sciences · 2025 · PMID 39940712

    Mitochondria serve an essential metabolic and energetic role in cellular activity, and their dysfunction has been implicated in a wide range of disorders, including cardiovascular conditions, neurodegenerative disorders, and metabolic syndromes. Mitochondria-targeted therapies, such as Elamipretide (SS-31, MTP-131, Bendavia), have consequently emerged as a topic of scientific and clinical interest. Elamipretide has a unique structure allowing for uptake in a variety of cell types and highly sele…

  2. 11.

    Nashine S · Cells · 2021 · PMID 34572131

    Aging contributes to the risk of development of ocular diseases including, but not limited to, Age-related Macular Degeneration (AMD) that is a leading cause of blindness in the United States as well as worldwide. Retinal aging, that contributes to AMD pathogenesis, is characterized by accumulation of drusen deposits, alteration in the composition of Bruch's membrane and extracellular matrix, vascular inflammation and dysregulation, mitochondrial dysfunction, and accumulation of reactive oxygen…

  3. 12.

    Shirley M · Drugs · 2026 · PMID 41335372

    Elamipretide (Forzinity™) is a mitochondrial cardiolipin binder being developed by Stealth BioTherapeutics for the treatment of a range of disorders featuring mitochondrial dysfunction. In September 2025, elamipretide was granted accelerated approval in the USA for use to improve muscle strength in adult and pediatric patients with Barth syndrome weighing ≥ 30 kg. With this accelerated approval, elamipretide became the first disease-specific treatment approved for Barth syndrome, an ultra-rare X…

  4. 13.

    Pavlović N, Križanac M, Kumrić M, Vukojević K, et al. · Cells · 2025 · PMID 40497970

    Mitochondrial dysfunction is a pivotal driver in the pathogenesis of acute kidney injury (AKI), chronic kidney disease (CKD), and congenital anomalies of the kidney and urinary tract (CAKUT). The kidneys, second only to the heart in mitochondrial density, rely on oxidative phosphorylation to meet the high ATP demands of solute reabsorption and filtration. Disrupted mitochondrial dynamics, such as excessive fission mediated by Drp1, exacerbate tubular apoptosis and inflammation in AKI models like…

  5. 14.

    Ciszewski P, Drelichowska A, Pikor D, Wiśniewska E, et al. · Romanian journal of ophthalmology · 2025 · PMID 40330967

    This review explores modern therapeutic options for the dry form of age-related macular degeneration (AMD), a condition representing one of the most significant challenges in ophthalmology due to its progressive nature and lack of effective treatment. The study discusses innovative approaches, evaluates available methods, and examines the potential of emerging technologies to improve patients' quality of life. A comprehensive review of current literature was conducted, being focused on therapies…

  6. 15.

    Obi C, Smith AT, Hughes GJ, Adeboye AA · Heart failure reviews · 2022 · PMID 35037146

    Although currently employed therapies for heart failure decrease overall mortality and improve patient quality of life temporarily, the disease is known to progress even for patients who receive all guideline-recommended therapies. This indicates that our concise understanding of heart failure and of disease progression is incomplete, and there is a need for new interventions that may augment, or even supplant, currently available options. A literature review reveals that an exciting, novel area…

  7. 16.

    Sabbah HN, Alder NN, Sparagna GC, Bruce JE, et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · PMID 40294492

    Mitochondria are cellular hubs integral for metabolism, signaling, and survival. Mitochondrial dysfunction is centrally involved in the aging process and an expansive array of disease states. Elamipretide is a novel mitochondria-targeting peptide that is under investigation for treating several disorders related to mitochondrial dysfunction. This review summarizes recent data that expand our understanding of the mechanism of action (MOA) of elamipretide. Elamipretide is a potential first-in-clas…

  8. 17.

    Bangeas A, Poulidou V, Liampas I, Marogianni C, et al. · International journal of molecular sciences · 2025 · PMID 40508218

    Mitochondria, the energy factories of human organisms, can be the cause of a variety of genetic disorders called mitochondrial myopathies. Mitochondrial diseases arise from genetic alterations in either mitochondrial DNA (mtDNA) or nuclear DNA (nDNA) and can manifest with great heterogeneity, leading to multiorgan dysfunction. The purpose of this article is to concisely review the pathophysiology, genetics and main clinical features of mitochondrial myopathies, focusing mainly on the treatment a…

  9. 18.

    Nhu NT, Xiao SY, Liu Y, Kumar VB, et al. · Frontiers in integrative neuroscience · 2021 · PMID 35111001

    Neural mitochondrial dysfunction, neural oxidative stress, chronic neuroinflammation, toxic protein accumulation, and neural apoptosis are common causes of neurodegeneration. Elamipretide, a small mitochondrially-targeted tetrapeptide, exhibits therapeutic effects and safety in several mitochondria-related diseases. In neurodegeneration, extensive studies have shown that elamipretide enhanced mitochondrial respiration, activated neural mitochondrial biogenesis

  10. 19.

    Tse BC, Dvoriantchikova G, Tao W, Gallo RA, et al. · Experimental eye research · 2020 · PMID 32758490

    Traumatic optic neuropathy (TON) can occur following blunt trauma to the orbit and can lead to permanent vision loss. In this study, we investigated the effectiveness of elamipretide (MTP-131), a small mitochondrially-targeted tetrapeptide, in conjunction with etanercept, a tumor necrosis factor (TNF) inhibitor, as neuroprotective agents of retinal ganglion cells (RGCs) after optic nerve trauma with sonication-induced TON (SI-TON) in mice. Treatment with intravitreal MTP-131 and subcutaneous eta…

  11. 20.

    Sabbah HN · Heart failure reviews · 2022 · PMID 34623544

    Barth syndrome is a rare and potentially fatal X-linked disease characterized by cardiomyopathy, skeletal muscle weakness, growth delays, and cyclic neutropenia. Patients with Barth syndrome are prone to high risk of mortality in infancy and the development of cardiomyopathy with severe weakening of the immune system. Elamipretide is a water-soluble, aromatic-cationic, mitochondria-targeting tetrapeptide that readily penetrates and transiently localizes to the inner mitochondrial membrane. Thera…

  12. 21.

    Tábara LC, Poveda J, Martin-Cleary C, Selgas R, et al. · Expert reviews in molecular medicine · 2014 · PMID 25104110

    Acute kidney injury (AKI) is a serious clinical condition with no effective treatment. Tubular cells are key targets in AKI. Tubular cells and, specifically, proximal tubular cells are extremely rich in mitochondria and mitochondrial changes had long been known to be a feature of AKI. However, only recent advances in understanding the molecules involved in mitochondria biogenesis and dynamics and the availability of mitochondria-targeted drugs has allowed the exploration of the specific role of…

  13. 22.

    Radovic M, Gartzke LP, Wink SE, van der Kleij JA, et al. · Biomolecules · 2025 · PMID 40427507

    Damage to mitochondrial DNA (mtDNA) results in defective electron transport system (ETS) complexes, initiating a cycle of impaired oxidative phosphorylation (OXPHOS), increased reactive oxygen species (ROS) production, and chronic low-grade inflammation (inflammaging). This culminates in energy failure, cellular senescence, and progressive tissue degeneration. Rapamycin and metformin are the most extensively studied longevity drugs. Rapamycin inhibits mTORC1, promoting mitophagy, enhancing mitoc…

  14. 23.

    de Barcelos IP, Emmanuele V, Hirano M · Current opinion in neurology · 2019 · PMID 31408013

    Although mitochondrial diseases impose a significant functional limitation in the lives of patients, treatment of these conditions has been limited to dietary supplements, exercise, and physical therapy. In the past few years, however, translational medicine has identified potential therapies for these patients. For patients with primary mitochondrial myopathies, preliminary phase I and II multicenter clinical trials of elamipretide indicate safety and suggest improvement in 6-min walk test (6MW…

  15. 24.

    Gandhi S, Sweeney HL, Hart CC, Han R, et al. · Cells · 2024 · PMID 39056750

    Duchenne muscular dystrophy (DMD) is a progressive neuromuscular disease caused by mutations to the dystrophin gene, resulting in deficiency of dystrophin protein, loss of myofiber integrity in skeletal and cardiac muscle, and eventual cell death and replacement with fibrotic tissue. Pathologic cardiac manifestations occur in nearly every DMD patient, with the development of cardiomyopathy-the leading cause of death-inevitable by adulthood. As early cardiac abnormalities are difficult to detect,…

  16. 25.

    Thapak P, Gomez-Pinilla F · Pharmacological research · 2024 · PMID 39243913

    Mitochondria provide the energy to keep cells alive and functioning and they have the capacity to influence highly complex molecular events. Mitochondria are essential to maintain cellular energy homeostasis that determines the course of neurological disorders, including traumatic brain injury (TBI). Various aspects of mitochondria metabolism such as autophagy can have long-term consequences for brain function and plasticity. In turn, mitochondria bioenergetics can impinge on molecular events as…

  17. 26.

    Zhu Y, Luo M, Bai X, Li J, et al. · Oxidative medicine and cellular longevity · 2022 · PMID 35707274

    Mitochondria are essential for eukaryotic cell activity and function, and their dysfunction is associated with the development and progression of renal diseases. In recent years, there has been a rapid development in mitochondria-targeting pharmacological strategies as mitochondrial biogenesis, morphology, and function, as well as dynamic changes in mitochondria, have been studied in disease states. Mitochondria-targeting drugs include nicotinamide mononucleotide, which supplements the NAD+ pool…

  18. 27.

    Chaturvedi RK, Beal MF · Annals of the New York Academy of Sciences · 2008 · PMID 19076459

    A large body of evidence from postmortem brain tissue and genetic analysis in humans and biochemical and pathological studies in animal models (transgenic and toxin) of neurodegeneration suggest that mitochondrial dysfunction is a common pathological mechanism. Mitochondrial dysfunction from oxidative stress, mitochondrial DNA deletions, pathological mutations, altered mitochondrial morphology, and interaction of pathogenic proteins with mitochondria leads to neuronal demise. Therefore, therapeu…

  19. 28.

    Zhao Q, Huang Y, Fu N, Cui C, et al. · Renal failure · 2024 · PMID 39248407

    As an important component of the glomerular filtration membrane, the state of the podocytes is closely related to kidney function, they are also key cells involved in aging and play a central role in the damage caused by renal aging. Therefore, understanding the aging process of podocytes will allow us to understand their susceptibility to injury and identify targeted protective mechanisms. In fact, the process of physiological aging itself can induce podocyte senescence. Pathological stresses,…

  20. 29.

    Gueven N, Nadikudi M, Daniel A, Chhetri J · Mitochondrion · 2017 · PMID 27476756

    Many reports have illustrated a tight connection between vision and mitochondrial function. Not only are most mitochondrial diseases associated with some form of vision impairment, many ophthalmological disorders such as glaucoma, age-related macular degeneration and diabetic retinopathy also show signs of mitochondrial dysfunction. Despite a vast amount of evidence, vision loss is still only treated symptomatically, which is only partially a consequence of resistance to acknowledge that mitocho…

  21. 30.

    Szeto HH · British journal of pharmacology · 2014 · PMID 24117165

    A decline in energy is common in aging, and the restoration of mitochondrial bioenergetics may offer a common approach for the treatment of numerous age-associated diseases. Cardiolipin is a unique phospholipid that is exclusively expressed on the inner mitochondrial membrane where it plays an important structural role in cristae formation and the organization of the respiratory complexes into supercomplexes for optimal oxidative phosphorylation. The interaction between cardiolipin and cytochrom…

  22. 31.

    Hu R, Shi J, Xie CM, Yao XL · Global challenges (Hoboken, NJ) · 2025 · PMID 40656216

    Dry eye disease (DED), a multifactorial ocular surface disorder characterized by tear film instability, is pathologically linked to oxidative damage. The accumulation of reactive oxygen species (ROS) across ocular tissues not only directly damages nucleic acids, proteins, and lipids, but also functions as an upstream driver of inflammation and tear hyperosmolarity, collectively disrupting cellular homeostasis. This review comprehensively delineates the mechanistic interplay between oxidative str…

  23. 32.

    Lv J, Li Y, Shi S, Xu X, et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022 · PMID 36271583

    Patients with heart failure (HF) usually present with skeletal muscle diseases of varying severity, ranging from early fatigue on exercise to sarcopenia, sarcopenic obesity or cachexia, and frailty, which are significant predictors of HF prognosis. Abnormal mitochondrial metabolism has been identified as one of the earliest signs of skeletal muscle injury in HF and is associated with pathological alterations in muscle, manifested as muscle wasting, myocyte atrophy and apoptosis, fiber type shift…

  24. 33.

    Zhang Y, Ma S, Chang W, Yu W, et al. · Journal of biotechnology · 2024 · PMID 39159753

    Mitochondria are crucial sites for biological oxidation and substance metabolism and plays a vital role in maintaining intracellular homeostasis. When mitochondria undergo oxidative damage or dysfunction, they can harm the organism, leading to various reactive oxygen species (ROS)-related diseases. Therefore, therapies targeting mitochondria are a strategy for treating multiple diseases. Many nanozymes can mimic antioxidant enzymes, which enables them to eliminate ROS to mitigate mitochondrial d…

  25. 34.

    Sinha JK, Jorwal K, Singh KK, Han SS, et al. · Molecular neurobiology · 2025 · PMID 39230868

    Mitochondria are central to cellular energy production, and their dysfunction is a major contributor to oxidative stress and chronic inflammation, pivotal factors in aging, and related diseases. With aging, mitochondrial efficiency declines, leading to an increase in ROS and persistent inflammatory responses. Therapeutic interventions targeting mitochondrial health show promise in mitigating these detrimental effects. Antioxidants such as MitoQ and MitoVitE, and supplements like coenzyme Q10 and…

  26. 35.

    Schwemmlein J, Maack C, Bertero E · Current heart failure reports · 2022 · PMID 35147851

    We review therapeutic approaches aimed at restoring function of the failing heart by targeting mitochondrial reactive oxygen species (ROS), ion handling, and substrate utilization for adenosine triphosphate (ATP) production. Mitochondria-targeted therapies have been tested in animal models of and humans with heart failure (HF). Cardiac benefits of sodium/glucose cotransporter 2 inhibitors might be partly explained by their effects on ion handling and metabolism of cardiac myocytes. The large ene…

  27. 36.

    Sabbah HN, Taylor C, Vernon HJ · Future cardiology · 2023 · PMID 37325898

    Barth syndrome (BTHS) is a rare genetic disorder caused by pathogenic variants in

  28. 37.

    Du X, Zeng Q, Luo Y, He L, et al. · Mitochondrion · 2024 · PMID 38237649

    Due to the pivotal role of mitochondria in the generation of adenosine triphosphate (ATP) and the regulation of cellular homeostasis, mitochondrial dysfunction may exert a profound impact on various physiological systems, potentially precipitating a spectrum of distinct diseases. Consequently, research pertaining to mitochondrial therapeutics has assumed increasing significance, warranting heightened scrutiny. In recent years, the field of mitochondrial therapy has witnessed noteworthy advanceme…

  29. 38.

    Sabbah HN · Heart failure reviews · 2021 · PMID 33001359

    Barth syndrome (BTHS) is a rare, X-linked recessive, infantile-onset debilitating disorder characterized by early-onset cardiomyopathy, skeletal muscle myopathy, growth delay, and neutropenia, with a worldwide incidence of 1/300,000-400,000 live births. The high mortality rate throughout infancy in BTHS patients is related primarily to progressive cardiomyopathy and a weakened immune system. BTHS is caused by defects in the TAZ gene that encodes tafazzin, a transacylase responsible for the remod…

  30. 39.

    Kezic A, Spasojevic I, Lezaic V, Bajcetic M · Oxidative medicine and cellular longevity · 2016 · PMID 27313826

    Kidney ischemia/reperfusion injury emerges in various clinical settings as a great problem complicating the course and outcome. Ischemia/reperfusion injury is still an unsolved puzzle with a great diversity of investigational approaches, putting the focus on oxidative stress and mitochondria. Mitochondria are both sources and targets of ROS. They participate in initiation and progression of kidney ischemia/reperfusion injury linking oxidative stress, inflammation, and cell death. The dependence…

  31. 40.

    Lores-Arnaiz S · Biology · 2026 · PMID 41677699

    Aging and neurodegenerative diseases are characterized by common features involving bioenergetics deficiencies, oxidative stress and alterations of calcium buffering. Mechanisms of mitochondrial-targeted drugs include the modulation of electron transport chain and oxidative phosphorylation, the binding to mitochondrial lipids, free-radical scavenging, calcium signaling, and possible effects on mitochondrial biogenesis and dynamics and on the regulation of mitophagic pathways. One of the main sit…

  32. 41.

    Pabla N, Bajwa A · Nephron · 2022 · PMID 34883481

    Acute kidney injury (AKI) is a common clinical disorder associated with decline in renal function because of ischemic and nephrotoxic insults. The pathophysiology of AKI involves multiple cellular mechanisms, such as kidney parenchymal cell (epithelial and endothelial) dysfunction and immune-cell infiltration. Mitochondrial injury which causes ATP depletion and triggers apoptosis and necrosis is at the heart of ischemia reperfusion injury (IRI). Pharmacological (SS-31 or MitoQ), cellular (dendri…

  33. 42.

    Manojlovic M, Zafirovic S, Tomic Naglic D, Stokic E, et al. · Biomolecules & biomedicine · 2025 · PMID 41128021

    Diabetes mellitus (DM) disrupts cellular homeostasis and is characterized by mitochondrial structural and functional impairments similar to those found in other metabolic disorders. Mitochondrial dysfunction (MD) leads to the excessive production of reactive oxygen species (ROS), which are central to the progression of cardiovascular (CV) disease-the leading cause of mortality associated with DM. ROS-driven oxidative stress (OS) is implicated in cardiac injury in both clinical and experimental c…

  34. 43.

    Pszczołowska M, Walczak K, Miśków W, Mroziak M, et al. · GeroScience · 2024 · PMID 38457008

    Alzheimer's disease (AD) is a neurodegenerative disorder and the most common cause of dementia globally. The pathogenesis of AD remains still unclear. The three main features of AD are extracellular deposits of amyloid beta (Aβ) plaque, accumulation of abnormal formation hyper-phosphorylated tau protein, and neuronal loss. Mitochondrial impairment plays an important role in the pathogenesis of AD. There are problems with decreased activity of multiple complexes, disturbed mitochondrial fusion, a…

  35. 44.

    Liu CJ, Wang LK, Tsai FM · Current issues in molecular biology · 2025 · PMID 40136430

    Chemotherapeutic agents play a crucial role in cancer treatment. However, their use is often associated with significant adverse effects, particularly cardiotoxicity. Drugs such as anthracyclines (e.g., doxorubicin) and platinum-based agents (e.g., cisplatin) cause mitochondrial damage, which is one of the main mechanisms underlying cardiotoxicity. These drugs induce oxidative stress, leading to an increase in reactive oxygen species (ROS), which in turn damage the mitochondria in cardiomyocytes…

  36. 45.

    Patel PS, Pabla NS, Bajwa A · Seminars in nephrology · 2026 · PMID 41027799

    Acute kidney injury (AKI) continues to pose a significant clinical burden, characterized by high morbidity and mortality rates. Emerging evidence has established mitochondrial dysfunction as a central driver in the pathogenesis of AKI, encompassing deficits in bioenergetics, excessive production of reactive oxygen species, and disruption of mitochondrial dynamics. Therapeutic interventions targeting mitochondrial pathways-most notably peptide-based agents such as SS-31-have demonstrated promisin…

  37. 46.

    Szeto HH, Liu S · Archives of biochemistry and biophysics · 2018 · PMID 30359579

    It has been proposed that a loss of bioenergetic capacity of cells contributes to the progressive loss of biological function with age. Aging is associated with loss of mitochondrial cristae membranes and inhibition of ATP production. Despite the many approaches being pursued for improving mitochondrial function, none of them directly targets the electron transport chain to improve ATP production. Recent studies have brought attention to cardiolipin as a unique target for promoting mitochondrial…

  38. 47.

    Szeto HH, Birk AV · Clinical pharmacology and therapeutics · 2014 · PMID 25188726

    The mitochondrial electron transport chain (ETC) plays a central role in energy generation in the cell. Mitochondrial dysfunctions diminish adenosine triphosphate (ATP) production and result in insufficient energy to maintain cell function. As energy output declines, the most energetic tissues are preferentially affected. To satisfy cellular energy demands, the mitochondrial ETC needs to be able to elevate its capacity to produce ATP at times of increased metabolic demand or decreased fuel suppl…

  39. 48.

    Naumovski P, De Spiegeleer B, Wakjira A, Van De Wiele C, et al. · Journal of cachexia, sarcopenia and muscle · 2025 · PMID 41231146

    Systemic muscle wasting is a prevalent condition that predicts adverse health outcomes in aging and disease. Despite its clinical relevance, the development of predictive biomarkers and effective pharmacological therapies remains limited. Peptides have recently gained attention for their diverse bioactive functions, positioning them as promising biomarkers and therapeutic agents for muscle wasting. This scoping review systematically identifies studies examining the direct association between wel…

  40. 49.

    Di K, Hu Y, Sun H, Meng T, et al. · Frontiers in physiology · 2026 · PMID 42291734

    Mitochondrial therapeutics have repeatedly fallen short of disease modification, in part because inner-membrane architecture constrains both molecular access and the reversibility of bioenergetic failure. Cardiolipin (CL), the signature phospholipid of the inner mitochondrial membrane, provides a mechanistically cohesive axis that links membrane mechanics to cristae organisation, respiratory-chain supercomplex stability and redox vulnerability. This Review summarises how CL biosynthesis and remo…

Research Articles

150
  1. 50.

    Zhao W, Xu Z, Cao J, Fu Q, et al. · Journal of neuroinflammation · 2019 · PMID 31747905

    It is widely accepted that mitochondria have a direct impact on neuronal function and survival. Oxidative stress caused by mitochondrial abnormalities play an important role in the pathophysiology of lipopolysaccharide (LPS)-induced memory impairment. Elamipretide (SS-31) is a novel mitochondrion-targeted antioxidant. However, the impact of elamipretide on the cognitive sequelae of inflammatory and oxidative stress is unknown. We utilized MWM and contextual fear conditioning test to assess hippo…

  2. 51.

    Zheng H, Ou J, Han H, Lu Q, et al. · Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025 · PMID 39848110

    Targeting mitochondrial ferroptosis presents a promising strategy for mitigating myocardial ischemia-reperfusion (I/R) injury. This study aims to evaluate the efficacy of the mitochondrial-targeted ferroptosis inhibitor SS-31@Fer-1 (elamipretide@ferrostatin1) in reducing myocardial I/R injury. SS-31@Fer-1 was synthesized and applied to H9C2 cells subjected to hypoxia/reoxygenation (H/R) to assess its protective effects. Cytotoxicity was evaluated using a cell counting kit-8 (CCK-8) assay, with l…

  3. 52.

    Zheng Z, Lei C, Liu H, Jiang M, et al. · Advanced healthcare materials · 2022 · PMID 35848825

    Mitochondrial dysfunction of cardiomyocytes (CMs) has been identified as a significant pathogenesis of early myocardial infarction (MI). However, only a few agents or strategies have been developed to improve mitochondrial dysfunction for the effective MI treatment. Herein, a reactive oxygen species (ROS)-responsive PAMB-G-TK/4-arm-PEG-SG hydrogel is developed for localized drug-loaded liposome delivery. Notably, the liposomes contain both elamipretide (SS-31) and sphingosine-1-phosphate (S1P),…

  4. 53.

    Hao Y, Fan Y, Feng J, Zhu Z, et al. · Cell communication and signaling : CCS · 2024 · PMID 38200543

    Cardiolipin (CL) plays a critical role in maintaining mitochondrial membrane integrity and overall mitochondrial homeostasis. Recent studies have suggested that mitochondrial damage resulting from abnormal cardiolipin remodelling is associated with the pathogenesis of diabetic kidney disease (DKD). Acyl-coenzyme A:lyso-cardiolipin acyltransferase-1 (ALCAT1) was confirmed to be involved in the progression of Parkinson's disease, diet-induced obesity and other ageing-related diseases by regulating…

  5. 54.

    Xia Y, Zhang Y, Du Y, Wang Z, et al. · Journal of nanobiotechnology · 2024 · PMID 38725011

    Dry Eye Disease (DED) is a prevalent multifactorial ocular disease characterized by a vicious cycle of inflammation, oxidative stress, and mitochondrial dysfunction on the ocular surface, all of which lead to DED deterioration and impair the patients' quality of life and social functioning. Currently, anti-inflammatory drugs have shown promising efficacy in treating DED; however, such drugs are associated with side effects. The bioavailability of ocular drugs is less than 5% owing to factors suc…

  6. 55.

    Zhang H, Chen Y, Li F, Wu C, et al. · Journal of neuroinflammation · 2023 · PMID 36609266

    Spinal cord injury (SCI) is a devastating injury that may result in permanent motor impairment. The active ingredients of medications are unable to reach the affected area due to the blood‒brain barrier. Elamipretide (SS-31) is a new and innovative aromatic cationic peptide. Because of its alternating aromatic and cationic groups, it freely crosses the blood‒brain barrier. It is also believed to decrease inflammation and protect against a variety of neurological illnesses. This study explored th…

  7. 56.

    Gong W, Liu Z, Wang Y, Huang W, et al. · Trends in biotechnology · 2025 · PMID 39689981

    Inflammatory bowel disease (IBD) is a chronic relapsing immune-mediated inflammatory disorder of the alimentary tract without exact etiology. Mitochondrial reactive oxygen species (mtROS) derived from mitochondrial dysfunction impair intestinal barrier function, increase gut permeability, and facilitate immune cell invasion, and, therefore, are considered to have a pivotal role in the pathogenesis of IBD. Here, we reprogrammed regulatory T cell (Treg)-derived exosomes loaded with the antioxidant…

  8. 57.

    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists · 2026 · PMID 41206662

  9. 58.

    Nie Y, Li J, Zhai X, Wang Z, et al. · Antioxidants (Basel, Switzerland) · 2023 · PMID 38136142

    Idiopathic pulmonary fibrosis (IPF) is a progressive fatal lung disease with a limited therapeutic strategy. Mitochondrial oxidative stress in macrophages is directly linked to IPF. Elamipretide(SS-31) is a mitochondrion-targeted peptide that has been shown to be safe and beneficial for multiple diseases. However, whether SS-31 alleviates IPF is unclear. In the present study, we used a bleomycin (BLM)-induced mouse model followed by SS-31 injection every other day to investigate its role in IPF…

  10. 59.

    Whitson JA, Martín-Pérez M, Zhang T, Gaffrey MJ, et al. · GeroScience · 2021 · PMID 34480713

    It has been demonstrated that elamipretide (SS-31) rescues age-related functional deficits in the heart but the full set of mechanisms behind this have yet to be determined. We investigated the hypothesis that elamipretide influences post-translational modifications to heart proteins. The S-glutathionylation and phosphorylation proteomes of mouse hearts were analyzed using shotgun proteomics to assess the effects of aging on these post-translational modifications and the ability of the mitochond…

  11. 60.

    Xiong L, Hu H, Zhu F, Shi H, et al. · International journal of molecular medicine · 2024 · PMID 39364755

    SS‑31 is a mitochondria‑targeting antioxidant that exhibits promising therapeutic potential for various diseases; however, its protective effect on diabetic cardiomyopathy (DCM) remains to be elucidated. At present, SS‑31 is considered not only to mitigate cardiolipin oxidative damage, but also to alleviate ferroptosis. The present study aimed to explore SS‑31 as a potential therapeutic strategy for improving DCM by alleviating mitochondria‑dependent ferroptosis. In vitro, H9C2 cells were expose…

  12. 61.

    Kuang X, Sun Y, Wang Z, Zhou S, et al. · Journal of applied toxicology : JAT · 2018 · PMID 29105116

    The hearing loss induced by aminoglycosides is caused by the permanent loss of mechanosensory hair cells of the inner ear. The aim of the present study is therefore to evaluate the protective effect of Bendavia, a novel antioxidant, on gentamicin-induced hair cell damage in zebrafish lateral lines. The results demonstrated the pretreatment of Bendavia exhibited dose-dependent protection against gentamicin in both acute and chronic exposure. We found that Bendavia at 150 μm conferred optimal prot…

  13. 62.

    Chavez JD, Tang X, Campbell MD, Reyes G, et al. · Proceedings of the National Academy of Sciences of the United States of America · 2020 · PMID 32554501

    Mitochondrial dysfunction underlies the etiology of a broad spectrum of diseases including heart disease, cancer, neurodegenerative diseases, and the general aging process. Therapeutics that restore healthy mitochondrial function hold promise for treatment of these conditions. The synthetic tetrapeptide, elamipretide (SS-31), improves mitochondrial function, but mechanistic details of its pharmacological effects are unknown. Reportedly, SS-31 primarily interacts with the phospholipid cardiolipin…

  14. 63.

    Silvaroli JA, Bisunke B, Kim JY, Stayton A, et al. · Journal of the American Society of Nephrology : JASN · 2024 · PMID 38530359

    Szeto–Schiller-31–mediated mitoprotection is phospholipid scramblase 3–dependent. Phospholipid scramblase 3 is required for recovery after AKI. The synthetic tetrapeptide Szeto–Schiller (SS)-31 shows promise in alleviating mitochondrial dysfunction associated with common diseases. However, the precise pharmacological basis of its mitoprotective effects remains unknown. To uncover the biological targets of SS-31, we performed a genome-scale clustered regularly interspaced short palindromic repeat…

  15. 64.

    Liu X, Wang FY, Chi S, Liu T, et al. · Brain research · 2024 · PMID 38521160

    Ferroptosis is a newly identified form of non-apoptotic regulated cell death (RCD) andplaysanimportantrole in epileptogenesis. The p38 mitogen-activated protein kinase (p38 MAPK) pathway has been confirmed to be involved in ferroptosis. The mitochondria-targeting antioxidant Elamipretide (SS-31) can reduce the generation of lipid peroxidation and the buildup of reactive oxygen species (ROS). Collectively, our present study was to decipher whether SS-31 inhibits ferroptosis via the p38 MAPK signa…

  16. 65.

    Gu Q, Wang Y, Zhang H, Yang W, et al. · PloS one · 2025 · PMID 40299935

    The aim of this research was to investigate if the mitochondria- targeting peptide SS-31 could serve as a protective measure against bleomycin-induced pulmonary fibrosis in mice. Mice were split into four groups named CON group, SS-31 group, BLM group, and the BLM + SS-31 group. SS-31 (intraperitoneal injection, 5mg/Kg) was administered daily from the day prior to the experiment for the control and model groups. Mice were euthanized after 28 days of the experiment, following which blood, broncho…

  17. 66.

    Patel N, Johnson MA, Vapniarsky N, Van Brocklin MW, et al. · Scientific reports · 2023 · PMID 36934127

    ischemia-reperfusion injury (IRI) after hemorrhage is potentiated by aortic occlusion or resuscitative endovascular balloon occlusion of the aorta (REBOA). Given the central role of mitochondrial injury in shock, we hypothesized that Elamipretide, a peptide that protects mitochondria, would mitigate IRI after hemorrhagic shock and REBOA. Twelve pigs were subjected to hemorrhagic shock and 45 min of REBOA. After 25 min of REBOA, animals received either saline or Elamipretide. Animals were transfu…

  18. 67.

    Wang C, Xu X, Dai S, Xie Z, et al. · ACS applied materials & interfaces · 2025 · PMID 40478241

    RNA-based therapies are often hampered by low RNA stability and cytoplasmic delivery efficiency. Coacervate droplets formed by liquid-liquid phase separation (LLPS) exhibit great potential in drug loading and transfection efficiency for delivering biomacromolecules into the cytoplasm due to their condensed and fluid nature. Here, we developed a type of coacervate droplet as the delivery vector formed by the LLPS of sodium hexametaphosphate (SHMP) and antioxidant peptide SS-31, followed by loadin…

  19. 68.

    Xie C, Huang J, Chen Y, Huang B, et al. · International immunopharmacology · 2025 · PMID 40633209

    Although N6-methyladenosine (m6A) modification and its reader protein YTHDF1 have been implicated in allergic airway inflammation, their roles in TDI-induced steroid-insensitive asthma remains unclear. β-catenin signaling is vital for airway inflammation and mitochondrial function in asthma. In this study, we investigated the interplay between β-catenin/TCF4 signaling and m6A-dependent regulation in a TDI-induced asthma model (TDI-AM). Mice were sensitized and challenged with TDI or house dust m…

  20. 69.

    Zhang YM, Wang YT, Wei RM, Li XY, et al. · Brain and behavior · 2024 · PMID 38688894

    The inflammation and synaptic dysfunction induced by mitochondrial dysfunction play essential roles in the learning and memory impairment associated with sleep dysfunction. Elamipretide (SS-31), a novel mitochondrion-targeted antioxidant, was proven to improve mitochondrial dysfunction, the inflammatory response, synaptic dysfunction, and cognitive impairment in models of cerebral ischemia, sepsis, and type 2 diabetes. However, the potential for SS-31 to improve the cognitive impairment induced…

  21. 70.

    Yao X, Lu Q, Wu Y, Liu J, et al. · Biopreservation and biobanking · 2024 · PMID 38648553

    The importance of ovarian cortical cryopreservation in fertility preservation is receiving increasing attention from reproductive specialists, and mitochondrial dysfunction is an important cause of reduced ovarian tissue cryopreservation. Elamipretide (SS-31) is a novel mitochondria-targeted antioxidant. However, whether it has a protective effect on mouse ovarian tissue cryopreservation remains to be studied. In this study, we examined follicular morphology and viability, mitochondrial function…

  22. 71.

    Pharaoh G, Kamat V, Kannan S, Stuppard RS, et al. · GeroScience · 2023 · PMID 37462785

    Aging muscle experiences functional decline in part mediated by impaired mitochondrial ADP sensitivity. Elamipretide (ELAM) rapidly improves physiological and mitochondrial function in aging and binds directly to the mitochondrial ADP transporter ANT. We hypothesized that ELAM improves ADP sensitivity in aging leading to rescued physiological function. We measured the response to ADP stimulation in young and old muscle mitochondria with ELAM treatment, in vivo heart and muscle function, and comp…

  23. 72.

    Imai T, Mishiro K, Takagi T, Isono A, et al. · Current neurovascular research · 2017 · PMID 27855593

    Mitochondria play a key role in cell survival by perfoming functions such as adenosine tri-phosphate (ATP) synthesis, regulation of apoptotic cell death, calcium storage. Hypoxic conditions induce mitochondrial dysfunction, which leads to endothelial injury in cerebral ischemia. Functional disorders include the following: collapse of mitochondrial membrane potential, reduction of ATP synthesis, and generation of reactive oxygen species (ROS). Bendavia, a novel tetra-peptide, has been reported to…

  24. 73.

    Eirin A, Li Z, Zhang X, Krier JD, et al. · Hypertension (Dallas, Tex. : 1979) · 2012 · PMID 23045468

    Revascularization improves blood pressure but not renal function in most patients with atherosclerotic renal artery stenosis (ARAS), possibly related to injury incurred during renal reperfusion. Bendavia, a novel tetrapeptide that inhibits mitochondrial permeability transition pore opening, reduces apoptosis, oxidative stress, and ischemia-reperfusion injury in experimental models. However, its potential for improving renal response to revascularization of chronic ARAS is unknown. We hypothesize…

  25. 74.

    Miyamoto S, Zhang G, Hall D, Oates PJ, et al. · The Journal of biological chemistry · 2020 · PMID 32277051

    Exposure to chronic hyperglycemia because of diabetes mellitus can lead to development and progression of diabetic kidney disease (DKD). We recently reported that reduced superoxide production is associated with mitochondrial dysfunction in the kidneys of mouse models of type 1 DKD. We also demonstrated that humans with DKD have significantly reduced levels of mitochondrion-derived metabolites in their urine. Here we examined renal superoxide production in a type 2 diabetes animal model, the

  26. 75.

    Hao Y, Hu J, Zhang Z, Guan Q, et al. · Cellular signalling · 2025 · PMID 40355014

    Perturbation of cardiolipin (CL) metabolism is associated with lipid nephrotoxicity. Recent findings provide new insights into the roles of CL-modulating proteins as critical determinants of podocyte function in chronic kidney disease (CKD). We previously demonstrated that Sirtuin 6 (Sirt6) is a compelling target inhibiting Angiotensin II (Ang II)-induced lipid dysregulation in podocytes. However, whether Sirt6 regulates podocyte CL metabolism is unknown. Renal biopsy specimens of patients with…

  27. 76.

    Patai R, Patel K, Csik B, Gulej R, et al. · GeroScience · 2025 · PMID 40169521

    Cerebral microhemorrhages (CMHs, also known as cerebral microbleeds) contribute to vascular cognitive impairment and dementia (VCID), with aging and hypertension being key risk factors. Mitochondrial oxidative stress is a hallmark of cerebrovascular aging, leading to endothelial dysfunction. This study tests the hypothesis that increased mitochondrial oxidative stress contributes to age-related CMH susceptibility and evaluates the mitochondrial-targeted antioxidative peptide SS-31 (elamipretide)…

  28. 77.

    Zhong L, Ren X, Ai Y, Liu Z · Neuromolecular medicine · 2023 · PMID 36333543

    Neuroinflammation and microglial activation are involved in the pathogenesis of sepsis-associated encephalopathy (SAE). Mitochondrial dynamics emerged as a new player in the regulation of immunological processes. In this study, we aimed at exploring the effects of mitochondrial-targeted antioxidant peptide SS-31 on cognitive function in mice with SAE. In mice, SS-31 was intraperitoneally administered for seven consecutive days after cecal ligation and puncture surgery. SS-31 improved cognitive p…

  29. 78.

    Duan S, Zhang Q, Zhu J, Wang J · Organogenesis · 2025 · PMID 40570323

    This study delves into the rejuvenating effects of SS-31 on aged human Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs), focusing on its potential to restore their diminished osteogenic differentiation capacity, a critical issue in geriatric medicine and bone tissue engineering. SS-31 significantly improved mitochondrial function, increasing ATP production by 35% and reducing ROS levels by 40% in aged BM-MSCs. Osteogenic differentiation was enhanced, as evidenced by a 2.8-fold increase in AL…

  30. 79.

    Eirin A, Ebrahimi B, Zhang X, Zhu XY, et al. · Cardiovascular research · 2014 · PMID 24947415

    The mechanisms responsible for renal injury in atherosclerotic renovascular disease (ARVD) are incompletely understood, and few therapeutic options are available to reverse it. We hypothesized that chronic renal damage involves mitochondrial injury, and that mitochondrial protection would reduce renal fibrosis and dysfunction in ARVD pigs. Domestic pigs were studied after 10 weeks of ARVD or sham, treated for the last 4 weeks with daily subcutaneous injections (5 days/week) of vehicle or Bendavi…

  31. 80.

    Wu J, Hao S, Sun XR, Zhang H, et al. · Frontiers in cellular neuroscience · 2017 · PMID 28487636

    Mitochondria are supposed to be involved in the early pathogenesis of general anesthesia (GA)-induced neurotoxicity and long-term cognitive deficits in developing brains. However, effective pharmacologic agents targeted on mitochondria during GA exposure are lacking. This study explores the protective effects of mitochondrion-targeted antioxidant elamipretide (SS-31) on mitochondrial morphogenesis and cognition in developing rats exposed to isoflurane. Rat pups at postnatal day (PND) 7 were expo…

  32. 81.

    Kingren MS, Keeble AR, Galvan-Lara AM, Ogle JM, et al. · Molecular medicine (Cambridge, Mass.) · 2024 · PMID 39563237

    Sepsis, mainly caused by bacterial infections, is the leading cause of in-patient hospitalizations. After discharge, most sepsis survivors suffer from long-term medical complications, particularly chronic skeletal muscle weakness. To investigate this medical condition in detail, we previously developed a murine severe sepsis-survival model that exhibits long-term post-sepsis skeletal muscle weakness. While mitochondrial abnormalities were present in the skeletal muscle of the sepsis surviving mi…

  33. 82.

    Graham ZA, DeBerry JJ, Cardozo CP, Bamman MM · Physiological reports · 2022 · PMID 35611788

    Spinal cord injury (SCI) leads to major reductions in function, independent living, and quality of life. Disuse and paralysis from SCI leads to rapid muscle atrophy, with chronic muscle loss likely playing a role in the development of the secondary metabolic disorders often seen in those with SCI. Muscle disuse is associated with mitochondrial dysfunction. Previous evidence has suggested targeting the mitochondria with the tetrapeptide SS-31 is beneficial for muscle health in preclinical models…

  34. 83.

    Wang Y, Deng M, Wu Y, Zheng C, et al. · Biomaterials · 2025 · PMID 39742837

    Intervertebral disc degeneration (IDD) is a deleterious condition driven by localized inflammation and the associated disruption of the normal homeostatic balance between anabolism and catabolism, contributing to progressive functional abnormalities within the nucleus pulposus (NP). Despite our prior evidence demonstrating that a miR-21 inhibitor can have regenerative effects that counteract the progression of IDD, its application for IDD treatment remains limited by the inadequacy of current lo…

  35. 84.

    Eirin A, Williams BJ, Ebrahimi B, Zhang X, et al. · Journal of hypertension · 2014 · PMID 24048008

    Renovascular hypertension (RVHT) increases cardiovascular morbidity and mortality. Renal revascularization with percutaneous transluminal renal angioplasty and stenting (PTRS) may reverse RVHT but may not fully regress cardiac remodeling and damage, possibly due to persistent myocardial insults. Bendavia is a mitochondrial targeted peptide that reduces ischemic cardiomyopathy by improving mitochondrial function. However, its potential for attenuating residual myocardial damage after reversal of…

  36. 85.

    Lu Q, Yao X, Zheng H, Ou J, et al. · Heliyon · 2024 · PMID 39506934

    Superparamagnetic iron oxide nanoparticles (SPION) are widely used in cardiovascular applications. However, their potential to induce ferroptosis in myocardial cells post-ischemia-reperfusion hinders clinical adoption. We investigated the mechanisms behind SPION-induced cytotoxicity in myocardial cells and explored whether co-loading SPION with SS-31 (a kind of mitochondrial-targeted antioxidant peptide) could counteract this toxicity. To create SPION@SS-31, SS-31 was physically adsorbed onto SP…

  37. 86.

    Zhang X, Zhang Y, Zhang M, Nakagawa Y, et al. · The American journal of sports medicine · 2022 · PMID 35862638

    Studies in our laboratory have demonstrated mitochondrial dysfunction in human and animal models of supraspinatus tendinopathy. SS-31 (elamipretide) has been reported to improve mitochondrial function and to be effective in clinical trials for several diseases. The potential of SS-31 in treating tendinopathy has not been explored. SS-31 would improve mitochondrial function in human tenocytes sampled from patients with tendinopathy. Controlled laboratory study. Healthy tenocytes were obtained fro…

  38. 87.

    Song Z, Ban Z, Zhao H, Mei X · Neurochemistry international · 2026 · PMID 42082001

    Spinal cord injury (SCI) induces secondary damage characterized by mitochondrial dysfunction, oxidative stress, and apoptosis, which collectively impede neurological recovery. Elamipretide (SS-31) is a mitochondria-targeting peptide with potential neuroprotective effects. Here, we investigated whether SS-31 improves functional outcomes after contusive SCI and explored associated mechanisms. In a mouse thoracic contusion model, SS-31 treatment significantly enhanced locomotor recovery and gait pe…

  39. 88.

    Bao W, Liu S, Du C, Liu J, et al. · Journal of controlled release : official journal of the Controlled Release Society · 2026 · PMID 41512967

    Sarcopenia is a degenerative skeletal muscle disorder closely associated with aging, characterized by the gradual loss of muscle mass and function, which severely impacts the quality of life in the elderly. In general, the severity of sarcopenia varies significantly among different patients and across different muscle groups, which increases the complexity and challenge of sarcopenia treatment. Based on the core pathological mechanism of sarcopenia, namely the deficiency of Nicotinamide adenine…

  40. 89.

    Mo Y, Deng S, Ai Y, Li W · Biochemical and biophysical research communications · 2024 · PMID 38581954

    SS-31 is a mitochondria-targeting short peptide. Recent studies have indicated its hepatoprotective effects. In our study, we investigated the impact of SS-31 on LPS-induced autophagy in HepG2 cells. The results obtained from a dual-fluorescence autophagy detection system revealed that SS-31 promotes the formation of autolysosomes and autophagosomes, thereby facilitating autophagic flux to a certain degree. Additionally, both ELISA and qPCR analyses provided further evidence that SS-31 safeguard…

  41. 90.

    Dong W, Zhang W, Huang L, Xiao L, et al. · Journal of advanced research · 2026 · PMID 41831680

    Cardiolipins (CLs) are mitochondria-specific phospholipids critically involved in neurological disorders. However, their roles in cerebral ischemia/reperfusion (I/R) injury remains largely underexplored. This study aimed to characterize CL alterations following cerebral I/R injury, identify potential mechanisms underlying CL loss, and investigate the pathophysiological effects of these changes. Ischemic stroke was modeled by using middle cerebral occlusion/reperfusion (MCAO/R) in mice and oxygen…

  42. 91.

    Ji Y, Ma Y, Ma Y, Wang Y, et al. · Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2024 · PMID 38411634

    Neuroinflammation is crucial in the development of postoperative cognitive dysfunction (POCD), and microglial activation is an active participant in this process. SS-31, a mitochondrion-targeted antioxidant, is widely regarded as a potential drug for neurodegenerative diseases and inflammatory diseases. In this study, we sought to explore whether SS-31 plays a neuroprotective role and the underlying mechanism. Internal fixation of tibial fracture was performed in 18-month-old mice to induce surg…

  43. 92.

    Shang L, Ren H, Wang S, Liu H, et al. · Oxidative medicine and cellular longevity · 2021 · PMID 33986918

    Ischemia-reperfusion injury (IRI) is a common complication in liver surgeries. It is a focus to discover effective treatments to reduce ischemia-reperfusion injury. Previous studies show that oxidative stress and inflammation response contribute to the liver damage during IRI. SS-31 is an innovated mitochondrial-targeted antioxidant peptide shown to scavenge reactive oxygen species and decrease oxidative stress, but the protective effects of SS-31 against hepatic IRI are not well understood. The…

  44. 93.

    Mitchell W, Tamucci JD, Ng EL, Liu S, et al. · eLife · 2022 · PMID 35913044

    Mitochondria play a central role in metabolic homeostasis, and dysfunction of this organelle underpins the etiology of many heritable and aging-related diseases. Tetrapeptides with alternating cationic and aromatic residues such as SS-31 (elamipretide) show promise as therapeutic compounds for mitochondrial disorders. In this study, we conducted a quantitative structure-activity analysis of three alternative tetrapeptide analogs, benchmarked against SS-31, that differ with respect to aromatic si…

  45. 94.

    Vieira Neto E, Wang M, Szuminsky AJ, Ferraro L, et al. · Journal of inherited metabolic disease · 2026 · PMID 41500837

    Mitochondrial trifunctional protein (TFP) deficiency is an inherited disorder of long-chain fatty acid β-oxidation (FAO). TFP is a heteromeric enzyme composed of two α and two β-subunits. Despite early detection and dietary treatment, TFP deficiency patients often develop hypoglycemia, rhabdomyolysis, cardiomyopathy, and peripheral neuropathy. Degenerative retinopathy and milder peripheral neuropathy occur in patients with an isolated deficiency of the αTFP subunit of long-chain 3-hydroxyacyl-Co…

  46. 95.

    Imai T, Matsubara H, Nakamura S, Hara H, et al. · Neuroscience · 2020 · PMID 32738431

    After ischemic stroke, oxygen and nutrition depletion induce mitochondrial dysfunction, which aggravates brain injury. Bendavia, a mitochondria-targeted tetra-peptide, has anti-oxidative and anti-inflammatory activities. We previously reported that bendavia protected human brain microvascular endothelial cells against oxygen/glucose deprivation (OGD)-induced damage via preserving mitochondrial function. The effects of bendavia on mitochondrial function include the inhibition of reactive oxygen s…

  47. 96.

    Qian W, Liu D, Liu J, Liu M, et al. · Small (Weinheim an der Bergstrasse, Germany) · 2025 · PMID 39713820

    Mitochondrial dysfunction plays an important role in neuroinflammation and cognitive impairment in Alzheimer's disease (AD). Herein, this work designs a mitochondria-targeted micelle CsA-TK-SS-31 (CTS) to block the progression of AD by simultaneously alleviating mitochondrial dysfunction in microglia and neurons. The mitochondria-targeted peptide SS-31 drives cyclosporin A (CsA) to penetrate the blood-brain barrier (BBB) and delivers CsA to mitochondria of microglia and neurons in the brains of…

  48. 97.

    Jiang T, Zhang H, Sun Y, Ji X, et al. · Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026 · PMID 41136322

    Accumulating evidence suggests that ferroptosis and mitochondrial dysfunction contribute significantly to brain injury following cardiac arrest (CA) and resuscitation. SS-31, a novel mitochondria-targeting peptide, has demonstrated protective effects against mitochondrial dysfunction induced by ischemia/reperfusion injury. This study aimed to investigate the neuroprotective effects of SS-31 in post-CA brain injury and clarify the underlying signaling mechanisms. An in vivo rat model of CA and re…

  49. 98.

    Ehlers JP, Hu A, Boyer D, Cousins SW, et al. · Ophthalmology science · 2025 · PMID 39605874

    This study evaluated the safety and efficacy of elamipretide in dry age-related macular degeneration (AMD) with noncentral geographic atrophy (GA). ReCLAIM-2 was a prospective, phase II, randomized, placebo-controlled, double-masked, multicenter trial (NCT03891875). Patients aged ≥55 years with ≥1 eye with dry AMD with GA were enrolled. Administration of daily subcutaneous elamipretide 40 mg was investigated in subjects for 48 weeks followed by a 4-week follow-up period. The primary efficacy end…

  50. 99.

    Liu Y, Fu H, Wu Y, Nie B, et al. · Frontiers in aging neuroscience · 2021 · PMID 33732135

    Neuroinflammation has been recognized as a major cause for neurocognitive diseases. Although the hippocampus has been considered an important region for cognitive dysfunction, the influence of hippocampal neuroinflammation on brain functional connectivity (FC) has been rarely studied. In this study, lipopolysaccharide (LPS) was used to induce systemic inflammation and neuroinflammation in the aged rat brain, while elamipretide (SS-31) was used for treatment. Systemic and hippocampal inflammation…

  51. 100.

    Brown DA, Hale SL, Baines CP, del Rio CL, et al. · Journal of cardiovascular pharmacology and therapeutics · 2014 · PMID 24288396

    We recently showed that Bendavia, a novel mitochondria-targeting peptide, reduced infarction and no-reflow across several experimental models. The purpose of this study was to determine the therapeutic timing and mechanism of action that underlie Bendavia's cytoprotective property. In rabbits exposed to in vivo ischemia/reperfusion (30/180 min), Bendavia administered 20 minutes prior to reperfusion (0.05 mg/kg/h, intravenously) reduced myocardial infarct size by ∼50% when administered for either…

  52. 101.

    Petcherski A, Trudeau KM, Wolf DM, Segawa M, et al. · Journal of molecular biology · 2018 · PMID 30389435

    Elamipretide is a tetrapeptide that restores defects in mitochondrial function, binds to cardiolipin, and is being tested in clinical trials for mitochondria-related diseases. However, whether elamipretide modulates mitochondrial quality control and dynamics, processes essential to preserve mitochondrial function, is unclear. Thus, we tested the effects of elamipretide on mitochondrial morphology, mitophagosome formation, and their early disruption induced by excess nutrients in INS1 β-cells. El…

  53. 102.

    Zhao C, Zhuang X, Gao J · Drug discoveries & therapeutics · 2026 · PMID 41260682

    Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder caused by tafazzin mutations that impair cardiolipin remodeling, leading to mitochondrial dysfunction and symptoms such as cardiomyopathy, myopathy, and neutropenia. On September 19, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to elamipretide, the first therapy directly targeting the mitochondrial etiology of BTHS. Elamipretide binds to cardiolipin on the inner mitochondrial membrane, stabilizing r…

  54. 103.

    Swain L, Bhave S, Qiao X, Reyelt L, et al. · Circulation · 2024 · PMID 38235580

    Cardiolipin is a mitochondrial-specific phospholipid that maintains integrity of the electron transport chain (ETC) and plays a central role in myocardial ischemia/reperfusion injury. Tafazzin is an enzyme that is required for cardiolipin maturation. Venoarterial extracorporeal membrane oxygenation (VA-ECMO) use to provide hemodynamic support for acute myocardial infarction has grown exponentially, is associated with poor outcomes, and is under active clinical investigation, yet the mechanistic…

  55. 104.

    Luo D, Mao Y, Zhang S, Shen S, et al. · Journal of photochemistry and photobiology. B, Biology · 2025 · PMID 39970726

    It is widely recognized that ultraviolet (UV) radiation primarily catalyses photodamage in the skin by generating reactive oxygen species (ROS). In this study, we developed a novel antioxidant complex, Exo-SS31, by loading the antioxidant peptide SS31 (also known as MTP-131, elamipretide) into milk-derived exosomes. Our findings indicate that Exo-SS31 is an effective antioxidant capable of mitigating Human dermal fibroblast (HDF) damage induced by ultraviolet exposure, suppressing ROS production…

  56. 105.

    Wang SX, Yin XY, Jian JX, Ji MH, et al. · Brain research · 2025 · PMID 40571047

    Sepsis-associated encephalopathy (SAE) is a prevalent and significant neurological complication that arises following sepsis, for which there is currently no effective treatment. Environmental enrichment (EE) has been shown to exert a neuroprotective effect through various mechanisms, including the promotion of neurogenesis, enhancement of neuroplasticity, and the inhibition of inflammatory processes. However, the precise mechanisms underlying these effects remain poorly understood. Utilizing RN…

  57. 106.

    Sabbah HN, Gupta RC, Kohli S, Wang M, et al. · Circulation. Heart failure · 2016 · PMID 26839394

    Elamipretide (MTP-131), a novel mitochondria-targeting peptide, was shown to reduce infarct size in animals with myocardial infarction and improve renal function in pigs with acute and chronic kidney injury. This study examined the effects of chronic therapy with elamipretide on left ventricular (LV) and mitochondrial function in dogs with heart failure (HF). Fourteen dogs with microembolization-induced HF were randomized to 3 months monotherapy with subcutaneous injections of elamipretide (0.5…

  58. 107.

    Xie M, Weng J, Li C, Liu Q, et al. · Lung · 2026 · PMID 41801306

    Ozone (O₃) exposure induces acute airway injury characterized by airway hyperresponsiveness (AHR) and airway mucus hypersecretion (AMH). Oxidative stress and mitochondria-derived reactive oxygen species (mtROS) are key contributors. We investigated and compared the protective mechanisms of N-acetylcysteine (NAC) and the mitochondria-targeted antioxidant Elamipretide (SS-31) in O₃-induced airway inflammation, AHR and AMH. Wild-type C57BL/6J mice received intraperitoneal NAC or SS-31 1 h before a…

  59. 108.

    Romanova N, Sule K, Issler T, Hebrok D, et al. · Journal of lipid research · 2025 · PMID 39880166

    The environmental pollutant cadmium (Cd) poses a threat to human health through the consumption of contaminated foodstuffs culminating in chronic nephrotoxicity. Mitochondrial dysfunction and excessive reactive oxygen species (ROS) are key to Cd cellular toxicity. Cd-lipid interactions have been less considered. We hypothesized Cd binding to the inner mitochondrial membrane (IMM) phospholipid cardiolipin (CL) and membrane rigidification underlies defective electron transfer by disrupted respirat…

  60. 109.

    Alam NM, Douglas RM, Prusky GT · Disease models & mechanisms · 2022 · PMID 34766182

    Age-related visual decline and disease due to neural dysfunction are major sources of disability that have resisted effective treatment. In light of evidence that visual impairment and mitochondrial dysfunction advance with age, we characterized age-related decline of spatial visual function in mice and investigated whether treatment of aged mice with the mitochondrion-penetrating peptide elamipretide that has been reported to improve mitochondrial function, would improve it. Impaired photopic a…

  61. 110.

    Heo J, Miller DL, Hoffman JR, Oberholtzer E, et al. · American journal of physiology. Cell physiology · 2025 · PMID 40465482

    Volumetric muscle loss (VML) is characterized by contractile weakness, dysfunctional mitochondrial bioenergetics, and poor rehabilitation plasticity. A hyperpolarized mitochondrial membrane potential is one attribute of the dysfunction bioenergetics and can lead to excessive reactive oxygen species (ROS) emissions. The primary objective of this study was to define the role of acute ROS emissions after VML injury. Male C57BL/6J mice were randomized into experimental and control groups. A time cou…

  62. 111.

    Bai H, Zhang Y, Tian S, Hu R, et al. · Cryobiology · 2020 · PMID 32240641

    As a technique widely used in assisted reproduction, human spermatozoa cryopreservation makes it possible to conserve functional sperm for a long time, but the impact of cryodamage on sperm during the process could not be ignored. The objective of the present study was to investigate the efficacy of Elamipretide, a novel small mitochondrial targeting short cytoprotective peptide, in attenuating cryodamage during spermatozoa cryopreservation. Semen samples were collected and cryopreserved in free…

  63. 112.

    Daneshgar N, Liang PI, Lan RS, Horstmann MM, et al. · Kidney international · 2022 · PMID 34953771

    Pregnancy is proposed to aggravate cyst progression in autosomal dominant polycystic kidney disease (ADPKD) but Tolvaptan, the only FDA-approved drug for adult ADPKD, is not recommended for pregnant ADPKD patients because of potential fetal harm. Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide. Elamipretide was found to ameliorate the progression of kidney disease in pregnant Pkd1

  64. 113.

    Zhang W, Tam J, Shinozaki K, Yin T, et al. · Heart, lung & circulation · 2019 · PMID 29503242

    Cardiac arrest is one of the leading causes of death with a very high mortality rate. No therapeutic drug that can be administered during resuscitation has been reported. Mitochondrial dysfunction is believed to play an important role for the pathogenesis of cardiac arrest. SS-31, a tetra-peptide, has been shown to protect mitochondria from ischaemia/reperfusion injury. Therefore, we tested whether SS-31 improves rat survival after prolonged cardiac arrest. Rats were randomised into two groups.…

  65. 114.

    Zhu Y, Wang H, Fang J, Dai W, et al. · Oxidative medicine and cellular longevity · 2018 · PMID 30224944

    SS-31, a novel mitochondria-targeted peptide, has been proven to provide neuroprotection in a variety of neurological diseases. Its role as a mitochondrial reactive oxygen species (ROS) scavenger and the underlying pathophysiological mechanisms in traumatic brain injury (TBI) are still not well understood. The aim of the designed study was to investigate the potential neuroprotective effects of SS-31 and fulfill our understanding of the process of the mitochondrial change in the modified Marmaro…

  66. 115.

    Cortés-Rojo C, Vargas-Vargas MA · World journal of diabetes · 2024 · PMID 39493563

    In this editorial, we discuss an article by Wang

  67. 116.

    Zhang X, Bowen E, Zhang M, Szeto HH, et al. · The Journal of bone and joint surgery. American volume · 2022 · PMID 35984013

    Prior studies have demonstrated mitochondrial dysfunction in tendinopathy. The objective of this investigation was to explore the potential of SS-31 (elamipretide), a mitochondrial protectant, to improve mitochondrial function and promote tendon healing in a murine supraspinatus tendinopathy model. One hundred and twenty-six mice (252 limbs) were divided into 6 groups (42 limbs/group) that received (I) 4 weeks of impingement; (II) 8 weeks of impingement; (III) 8 weeks of impingement including 4…

  68. 117.

    Sweetwyne MT, Pippin JW, Eng DG, Hudkins KL, et al. · Kidney international · 2017 · PMID 28063595

    Although age-associated changes in kidney glomerular architecture have been described in mice and man, the mechanisms are unknown. It is unclear if these changes can be prevented or even reversed by systemic therapies administered at advanced age. Using light microscopy and transmission electron microscopy, our results showed glomerulosclerosis with injury to mitochondria in glomerular epithelial cells in mice aged 26 months (equivalent to a 79-year-old human). To test the hypothesis that reduci…

  69. 118.

    Ravenscraft B, Lee DH, Dai H, Watson AL, et al. · International journal of molecular sciences · 2025 · PMID 40244206

    Spinal cord injury (SCI) affects millions globally, leading to severe motor and sensory deficits with no effective clinical treatment. Cardiolipin (CL), a mitochondria-specific phospholipid, plays a critical role in bioenergetics and apoptosis. Emerging evidence suggests that CL alterations contribute to secondary SCI pathology, but their precise role and underlying mechanisms remain fully understudied. In this study, we investigated the protective effects of SS-31 on CL alteration, neuronal dea…

  70. 119.

    Nguyen ST, Otoi T, Namula Z, Widodo OS, et al. · Animals : an open access journal from MDPI · 2025 · PMID 40941292

    Mitochondrial-targeted antioxidant supplementation is promising for in vitro culture of mammalian embryos. Elamipretide (SS-31) is a synthetic tetrapeptide that binds to the inner mitochondrial membrane, contributing to the prevention of oxidative stress. In this study, the effects of SS-31 supplementation in maturation medium on the developmental competence of porcine oocytes and its protective function were evaluated. Porcine oocytes were matured in maturation medium with SS-31 at 0.001, 0.01,…

  71. 120.

    Yap C, Wanga S, Wüst RCI, van Os BW, et al. · Vascular pharmacology · 2024 · PMID 38272196

    The antibiotic doxycycline is known to inhibit inflammation and was therefore considered as a therapeutic to prevent abdominal aortic aneurysm (AAA) growth. Yet mitochondrial dysfunction is a key-characteristic of clinical AAA disease. We hypothesize that doxycycline impairs mitochondrial function in the aorta and aortic smooth muscle cells (SMCs). Doxycycline induced mitonuclear imbalance, reduced proliferation and diminished expression of typical contractile smooth muscle cell (SMC) proteins.…

  72. 121.

    Shi J, Dai W, Hale SL, Brown DA, et al. · Life sciences · 2015 · PMID 26431885

    We have observed that Bendavia, a mitochondrial-targeting peptide that binds the phospholipid cardiolipin and stabilizes the components of electron transport and ATP generation, improves cardiac function and prevents left ventricular remodeling in a 6week rat myocardial infarction (MI) model. We hypothesized that Bendavia restores mitochondrial biogenesis and gene expression, suppresses cardiac fibrosis, and preserves sarco/endoplasmic reticulum (SERCA2a) level in the noninfarcted border zone of…

  73. 122.

    Ye P, Liu H, Qin Y, Li Z, et al. · Chemico-biological interactions · 2024 · PMID 39069114

    Smoking is a well-established risk factor for several oral diseases, including oral cancer, oral leukoplakia and periodontitis, primarily related to reactive oxygen species (ROS). SS-31, a mitochondria-targeting tetrapeptide, has exhibited demonstrable efficacy in medical conditions by attenuating mitochondrial ROS production. However, its potential in the treatment of oral diseases remains underexplored. The aim of this study was to investigate the therapeutic potential of SS-31 in mitigating s…

  74. 123.

    Allen ME, Pennington ER, Perry JB, Dadoo S, et al. · Communications biology · 2020 · PMID 32680996

    Mitochondrial dysfunction contributes to cardiac pathologies. Barriers to new therapies include an incomplete understanding of underlying molecular culprits and a lack of effective mitochondria-targeted medicines. Here, we test the hypothesis that the cardiolipin-binding peptide elamipretide, a clinical-stage compound under investigation for diseases of mitochondrial dysfunction, mitigates impairments in mitochondrial structure-function observed after rat cardiac ischemia-reperfusion. Respiromet…

  75. 124.

    Ahmed Z, Abdul Rehman F, Bokhari SFH · Cureus · 2025 · PMID 41058805

    Refractory heart failure (HF) remains a pressing clinical challenge despite substantial progress in pharmacologic and device-based interventions. While current therapies target neurohormonal, hemodynamic, and metabolic derangements, a crucial element of cellular dysfunction often remains overlooked: mitochondrial health. Mitochondrial dysfunction plays a central role in the pathogenesis and progression of HF, contributing to bioenergetic failure, oxidative stress, and cardiomyocyte death. Recent…

  76. 125.

    Bai J, Yang Y, Wu D, Yang F · Clinical and experimental pharmacology & physiology · 2021 · PMID 33774859

    Evidence has shown that effects from oxidative stress induced damage of retinal or human retinal pigment epithelial (RPE) cells. Antioxidant supplementation is a plausible strategy to avoid oxidative stress and maintain the function of retina. d-Arg-2,6-dimethyltyrosine-Lys-Phe-NH2 (SS-31) has been used in the treatment of many diseases. In this study, we found that SS-31 attenuated hydrogen peroxide (H

  77. 126.

    Kloner RA, Hale SL, Dai W, Gorman RC, et al. · Journal of the American Heart Association · 2012 · PMID 23130143

    Manifestations of reperfusion injury include myocyte death leading to infarction, contractile dysfunction, and vascular injury characterized by the "no-reflow" phenomenon. Mitochondria-produced reactive oxygen species are believed to be centrally involved in each of these aspects of reperfusion injury, although currently no therapies reduce reperfusion injury by targeting mitochondria specifically. We investigated the cardioprotective effects of a mitochondria-targeted peptide, Bendavia (Stealth…

  78. 127.

    Campbell MD, Samuelson AT, Chiao YA, Sweetwyne MT, et al. · GeroScience · 2023 · PMID 36840897

    The pathology of aging impacts multiple organ systems, including the kidney and skeletal and cardiac muscles. Long-term treatment with the mitochondrial-targeted peptide elamipretide has previously been shown to improve in vivo mitochondrial function in aged mice, which is associated with increased fatigue resistance and treadmill performance, improved cardiovascular diastolic function, and glomerular architecture of the kidney. However, elamipretide is a short tetrameric peptide that is not ora…

  79. 128.

    Liu Y, Cai J, Shen J, Dong W, et al. · Human molecular genetics · 2021 · PMID 34387346

    Friedreich ataxia (FRDA) is a serious hereditary neurodegenerative disease, mostly accompanied with hypertrophic cardiomyopathy, caused by the reduced expression of frataxin (FXN). However, there is still no effective treatment. Our previous studies have shown that SS-31, a mitochondrion-targeted peptide, is capable to upregulate the expression of FXN and improve the mitochondrial function in cells derived from FRDA patients. To further explore the potential of SS-31, we used the GAA expansion-b…

  80. 129.

    Shan Z, Wang Y, Qiu T, Zhou Y, et al. · The journal of headache and pain · 2023 · PMID 37271805

    Migraine is the second highest cause of disability worldwide, bringing a huge socioeconomic burden. Improving mitochondrial function has promise as an effective treatment strategy for migraine. Szeto-Schiller peptide (SS-31) is a new mitochondria-targeted tetrapeptide molecule that has been shown to suppress the progression of diseases by restoring mitochondrial function, including renal disease, cardiac disease, and neurodegenerative disease. However, whether SS-31 has a therapeutic effect on m…

  81. 130.

    Du W, Jiang Y, Wu L, Liang Y, et al. · ACS applied materials & interfaces · 2025 · PMID 41288605

    Mitochondrial dysfunction is a hallmark of early diabetes. Previous studies suggest that Argonaute-2 (AGO-2) supplementation enhances mitochondrial gene expression and improves cellular stability. Here, we investigated AGO-2 expression during diabetic myocardial injury and designed a multifunctional nanocarrier to selectively deliver AGO-2 to cardiac mitochondria, aiming to restore mitochondrial homeostasis and mitigate oxidative stress. We employed an extremely small iron oxide (ESIO) nanoparti…

  82. 131.

    Wu X, Pang Y, Zhang Z, Li X, et al. · Acta biochimica et biophysica Sinica · 2019 · PMID 30811524

    To investigate the neuroprotective effects of the mitochondria-targeted antioxidant Szeto-Schiller peptide 31 (SS-31) in a rat experimental glaucoma model, SS-31 was intraperitoneally (IP) injected into Sprague-Dawley rats, followed by intracameral injection of polystyrene microspheres to induce elevated intraocular pressure (IOP). After 6 weeks, electroretinography (ERG) and flash visual-evoked potentials (F-VEPs) were recorded to assess retinal function. Hematoxylin-eosin staining was performe…

  83. 132.

    Dai W, Shi J, Gupta RC, Sabbah HN, et al. · Journal of cardiovascular pharmacology · 2014 · PMID 25165999

    AB We evaluated the post-myocardial infarction (MI) therapeutic effects of Bendavia. Two hours after coronary artery ligation, rats were randomized to receive chronic Bendavia treatment (n = 28) or water (n = 26). Six weeks later, Bendavia significantly reduced scar circumference (39.7% +/- 2.2%) compared with water treatment (47.4% +/- 0.03%, P = 0.024) and reduced left ventricular (LV) volume by 8.9% (P = 0.019). LV fractional shortening was significantly improved by Bendavia (28.8% +/- 1.7%)…

  84. 133.

    Whitson JA, Bitto A, Zhang H, Sweetwyne MT, et al. · Aging cell · 2020 · PMID 32779818

    The effects of two different mitochondrial-targeted drugs, SS-31 and NMN, were tested on Old mouse hearts. After treatment with the drugs, individually or Combined, heart function was examined by echocardiography. SS-31 partially reversed an age-related decline in diastolic function while NMN fully reversed an age-related deficiency in systolic function at a higher workload. Metabolomic analysis revealed that both NMN and the Combined treatment increased nicotinamide and 1-methylnicotinamide lev…

  85. 134.

    Russo S, De Rasmo D, Signorile A, Corcelli A, et al. · Scientific reports · 2022 · PMID 36400945

    Barth Syndrome (BTHS), a genetic disease associated with early-onset cardioskeletal myopathy, is caused by loss-of-function mutations of the TAFAZZIN gene, which is responsible for remodeling the mitochondrial phospholipid cardiolipin (CL). Deregulation of CL biosynthesis and maturation in BTHS mitochondria result in a dramatically increased monolysocardiolipin (MLCL)/CL ratio associated with bioenergetic dysfunction. One of the most promising therapeutic approaches for BTHS includes the mitocho…

  86. 135.

    Mitchell W, Pharaoh G, Tyshkovskiy A, Campbell M, et al. · Aging cell · 2025 · PMID 40080911

    Aging-related decreases in cardiac and skeletal muscle function are strongly associated with various comorbidities. Elamipretide (ELAM), a novel mitochondria-targeted peptide, has demonstrated broad therapeutic efficacy in ameliorating disease conditions associated with mitochondrial dysfunction across both clinical and pre-clinical models. Herein, we investigated the impact of 8-week ELAM treatment on pre- and post-measures of C57BL/6J mice frailty, skeletal muscle, and cardiac muscle function,…

  87. 136.

    Ballarò R, Lopalco P, Audrito V, Beltrà M, et al. · Cancers · 2021 · PMID 33670497

  88. 137.

    Graham ZA, DeBerry JJ, Cardozo CP, Bamman MM · Physiological reports · 2021 · PMID 33611851

    Spinal cord injury (SCI) leads to rapid muscle atrophy due to paralysis/paresis and subsequent disuse. SS-31 is a mitochondrial-targeting peptide that has shown efficacy in protecting skeletal muscle mass and function in non-SCI models of muscle wasting. We aimed to determine if SS-31 could prevent muscle loss after SCI. Male C57BL/6 mice aged 9 weeks underwent sham surgery or 50 kdyne contusion SCI and were administered daily injections of vehicle or 5 mg/kg SS-31 for 14 d. Both SCI groups had…

  89. 138.

    Cai J, Jiang Y, Zhang M, Zhao H, et al. · Journal of physiology and biochemistry · 2018 · PMID 29589186

    Hind limb ischemia-reperfusion injury is an important pathology in vascular surgery. Reactive oxygen species are thought to be involved in the pathogenesis of hind limb ischemia-reperfusion injury. SS-31, which belongs to a family of mitochondrion-targeted peptide antioxidants, was shown to reduce mitochondrial reactive oxygen species production. In this study, we investigated whether the treatment of SS-31 could protect hind limb from ischemia-reperfusion injury in a mouse model. The results sh…

  90. 139.

    Eirin A, Ebrahimi B, Kwon SH, Fiala JA, et al. · Journal of the American Heart Association · 2016 · PMID 27247333

    Renovascular hypertension (RVH) impairs cardiac structure and left ventricular (LV) function, but whether mitochondrial injury is implicated in RVH-induced myocardial damage and dysfunction has not been defined. We hypothesized that cardiac remodeling in swine RVH is partly attributable to cardiac mitochondrial injury. After 12 weeks of hypercholesterolemic (HC)-RVH or control (n=14 each), pigs were treated for another 4 weeks with vehicle or with the mitochondrial-targeted peptide (MTP), Bendav…

  91. 140.

    Grosser JA, Fehrman RL, Keefe D, Redmon M, et al. · BMC research notes · 2021 · PMID 34022923

    Elamipretide (SS31) is a mitochondria-targeted peptide that has reported functions of stabilizing mitochondrial cristae structure and improving mitochondrial bioenergetics. Several studies have documented cell protective features of this peptide, including impairment of intrinsic apoptosis by inhibiting the recruitment and activation of the pro-apoptotic BAX protein. We used live-cell imaging of ARPE-19 cells expressing fluorescently labeled BAX, cytochrome c, and a mitochondrial marker to inves…

  92. 141.

    Cerrato CP, Pirisinu M, Vlachos EN, Langel Ü · FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2015 · PMID 26195590

    Cell-penetrating peptides (CPPs) are short, nontoxic peptides with cationic and/or amphipathic properties able to cross the cellular membrane. CPPs are used for the delivery of a wide variety of cargoes, such as proteins, oligonucleotides, and therapeutic molecules. The aim of the present study was to synthesize unusually small novel CPPs targeting mitochondria based on the Szeto-Schiller peptide (SS-31) to influence intramitochondrial processes and to improve the biologic effects. All the pepti…

  93. 142.

    Sun S, Wu M, Zhang P, Sun L, Zhong W, Zheng S, Li Y, Li J, Li Q. · 2026 · PMID 42022751

    Cardiovascular diseases (CVDs) remain the leading cause of global mortality, with mitochondrial dysfunction serving as a central pathological hub in conditions such as atherosclerosis, myocardial ischemia-reperfusion injury and heart failure. Current mitochondrial-regulating drugs are severely limited by low bioavailability, short duration of action, poor targeting specificity and off-target effects, highlighting an urgent need for precise delivery systems. Nanocarriers, with tunable physicochem…

  94. 143.

    Zhang G, Sharma K. · 2024 · PMID 38749551

  95. 144.

    Ruiz-Ortega ED, Wilkaniec A, Juárez J, Adamczyk A. · 2025 · PMID 41339963

    Parkinson's disease (PD) is defined by the progressive loss of dopaminergic neurons and the accumulation of misfolded α-synuclein (α-syn), yet the molecular determinants of selective neuronal vulnerability remain unresolved. Increasing evidence implicates mitochondria-and particularly their membranes-as critical platforms where α-syn is toxic. This review highlights how α-syn engages mitochondrial membranes through two interconnected processes: classical aggregation and liquid‒liquid phase separ…

  96. 145.

    Chaudhari M, Makhloufi J, Doelling B, Kataria R, Bhatnagar A, Kalra D, Baba SP. · 2026 · PMID 41898746

    Heart failure (HF) with reduced ejection fraction is a systemic disorder that extends beyond cardiac dysfunction and involves peripheral organs, particularly skeletal muscle. Exercise intolerance and fatigue are the hallmark manifestations of HF that strongly predict morbidity and mortality. Accumulating evidence suggests that intrinsic skeletal muscle abnormalities are key contributors to exercise intolerance in HF. In HF, skeletal muscle undergoes metabolic remodeling characterized by shifts i…

  97. 146.

    Glogowski PA, Fogacci F, Algieri C, Cugliari A, Trombetti F, Nesci S, Cicero AFG. · 2025 · PMID 41462662

    Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, with a substantial proportion of events occurring prematurely. Atherosclerosis (AS), the central driver of cardiovascular pathology, results from the convergence of metabolic disturbances, vascular inflammation, and organelle dysfunction. Among intracellular organelles, mitochondria have emerged as critical regulators of vascular homeostasis. Beyond their canonical role in adenosine triphosphate (ATP) production, mitocho…

  98. 147.

    Mendias CL, Awan TM. · 2026 · PMID 41966639

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside of regulatory oversight. Our objecti…

  99. 148.

    Li G, Li T, Deng Y, Deng X, Chen C, Yu B, Zhang K. · 2025 · PMID 41542093

    <h4>Background</h4>Heterotopic ossification (HO) is a common degenerative disease following trauma. Tendon HO is primarily attributed to osteogenic differentiation of stem/progenitor cells within the tendon. However, the precise mechanism underlying this process remains unclear. Recent studies suggest that PTEN induced kinase 1 (PINK1)/Parkin-mediated mitophagy plays a crucial role in biomineralization. Adenine nucleotide translocase 1 (ANT1), an upstream regulator of the PINK1/Parkin pathway, m…

  100. 149.

    Tamucci JD, Zweifach A, Alder NN, May ER. · 2025 · PMID 41342375

    Several studies have used molecular dynamics (MD) simulations to examine the relationship between transmembrane potentials (ΔΨ<sub>m</sub>) and electroporation; however, research on how this relationship presents in complex membranes with heterogeneous lipid compositions is limited. Here, we use all-atom, double-bilayer MD simulations with explicitly modeled ΔΨ<sub>m</sub> voltages to compare how membranes with homogeneous vs heterogeneous lipid compositions respond to varying degrees of electro…

  101. 150.

    Thompson AD, Victor Santiago Raj P, Scholpa NE, Schnellmann RG. · 2025 · PMID 39855593

    The kidney is one of the most metabolically demanding organs in the human body and requires a large amount of energy, in the form of adenosine triphosphate (ATP), to perform and maintain normal kidney functions. To meet this energy demand, proximal tubule cells within the nephron segments of the renal cortex are mitochondrially dense with high oxygen consumption rates. Mitochondria are complex organelles involved in diverse cellular and molecular functions, including the production of ATP, calci…

  102. 151.

    Kan MH, Liu Y, Meng FQ, Fan L, Wu Y, Wang TL. · 2025 · PMID 41247543

    To investigate the role of endothelial glycocalyx (eGC) degradation in mediating the progression from systemic inflammation to neuroinflammation and cognitive impairment in aged rats, and to explore the protective effects of the mitochondrial-targeted peptide SS-31. Aged male Wistar rats (24 months) were assigned to four groups: Vehicle, LPS, LPS + SS-31, and SS-31 alone. Systemic inflammation was induced by intraperitoneal injection of lipopolysaccharide (LPS). SS-31 was administered 30 min pri…

  103. 152.

    Alia S, Pedriali G, Compagnucci P, Valeri Y, Membrino V, Di Crescenzo T, Tremoli E, Mazzanti L, Vignini A, Pinton P, Casella M. · 2026 · PMID 41744815

    Mitochondria are central regulators of cardiac homeostasis, integrating energy production, redox balance, calcium handling, and innate immune signaling. In cardiovascular disease (CVD), mitochondrial dysfunction acts as a unifying mechanism connecting oxidative stress, metabolic inflexibility, inflammation, and structural remodeling. Disturbances in mitochondrial quality control-encompassing fusion-fission dynamics, PINK1/Parkin- and receptor-mediated mitophagy, biogenesis, and proteostasis-comp…

  104. 153.

    Paillard M, Abdellatif M, Andreadou I, Bär C, Bertrand L, Brundel BJJM, Chiva-Blanch G, Davidson SM, Dawson D, Di Lisa F, Evans P, Giricz Z, Hausenloy DJ, Kleinbongard P, Lezoualc'h F, Liehn E, Maack C, Maguy A, Murphy E, Perrino C, Pesce M, Rainer PP, Streckfuss-Bömeke K, Thielmann M, Tian R, Tocchetti CG, Van Der Velden J, Van Linthout S, Zacchigna S, Krieg T. · 2025 · PMID 40320260

    Acute myocardial infarction (MI) remains a major cause of death and disability worldwide. No adjuvant treatment has yet been fully validated in patients to limit the progression from the initial tissue damage due to acute MI, to the development of heart failure. However, mitochondria have long been demonstrated to be a key target for cardioprotective strategies to reduce cell death that leads to left ventricular dysfunction and ultimately heart failure. While pre-clinical studies have investigat…

  105. 154.
  106. 155.

    Xiao X, Yan X, Liang C, Yang Y. · 2026 · PMID 41835065

    Alzheimer's disease (AD) is a gradual and irreversible decline in the brain's ability to function which is not only signified by amyloid-beta plaques and neurofibrillary tangles but also by and metabolic and mitochondrial changes that have a negative impact on the classical neuropathological hallmarks. It is becoming increasingly clear that the central roles in the process of synaptic dysfunction, neuronal death and cognitive decline are played by the brain's impaired glucose utilization, insuli…

  107. 156.

    Alotaibi K, Arulkumaran N, Dyson A, Singer M. · 2025 · PMID 39899361

    Mitochondrial reactive oxygen species (mROS) play a crucial physiological role in intracellular signalling. However, high levels of ROS can overwhelm antioxidant defences and lead to detrimental modifications in protein, lipid and DNA structure and function. Ischaemia-reperfusion injury is a multifaceted pathological state characterised by excessive production of mROS. There is a significant clinical need for therapies mitigating mitochondrial oxidative stress. To date, a variety of strategies h…

  108. 157.

    Fontecha-Barriuso M, Lopez-Diaz AM, Guerrero-Mauvecin J, Miguel V, Ramos AM, Sanchez-Niño MD, Ruiz-Ortega M, Ortiz A, Sanz AB. · 2022 · PMID 35883847

    Acute kidney injury (AKI) and chronic kidney disease (CKD) are interconnected conditions, and CKD is projected to become the fifth leading global cause of death by 2040. New therapeutic approaches are needed. Mitochondrial dysfunction and oxidative stress have emerged as drivers of kidney injury in acute and chronic settings, promoting the AKI-to-CKD transition. In this work, we review the role of mitochondrial dysfunction and oxidative stress in AKI and CKD progression and discuss novel therape…

  109. 158.

    Mastoor Y, Murphy E, Roman B. · 2025 · PMID 39744953

    Acute myocardial infarction (MI) is a leading cause of death worldwide. Although with current treatment, acute mortality from MI is low, the damage and remodeling associated with MI are responsible for subsequent heart failure. Reducing cell death associated with acute MI would decrease the mortality associated with heart failure. Despite considerable study, the precise mechanism by which ischemia and reperfusion (I/R) trigger cell death is still not fully understood. In this Review, we summariz…

  110. 159.

    Scott V, Delatycki MB, Tai G, Corben LA. · 2024 · PMID 39115603

    The life shortening nature of Friedreich Ataxia (FRDA) demands the search for therapies that can delay, stop or reverse its relentless trajectory. This review provides a contemporary position of drug and gene therapies for FRDA currently in phase 1 clinical trials and beyond. Despite significant scientific advances in the specificity of both compounds and targets developed and investigated, challenges remain for the advancement of treatments in a limited recruitment population. Currently therapi…

  111. 160.

    Granata S, Votrico V, Spadaccino F, Catalano V, Netti GS, Ranieri E, Stallone G, Zaza G. · 2022 · PMID 35453454

    Although there has been technical and pharmacological progress in kidney transplant medicine, some patients may experience acute post-transplant complications. Among the mechanisms involved in these conditions, ischemia/reperfusion (I/R) injury may have a primary pathophysiological role since it is one of the leading causes of delayed graft function (DGF), a slow recovery of the renal function with the need for dialysis (generally during the first week after transplantation). DGF has a significa…

  112. 161.

    Ortmann L, Velasco D, Cole J. · 2025 · PMID 39917770

    <h4>Background</h4>Barth syndrome (BTHS) is a rare genetic disease, with no approved curative therapies, characterized by abnormally developed cardiolipin, resulting in mitochondrial dysfunction. Cardiomyopathy, a common clinical manifestation of BTHS, often appears in infancy. Elamipretide, an investigational drug that binds to cardiolipin on the inner mitochondrial membrane, leads to improved membrane stability, enhanced adenosine triphosphate production, and reduced reactive oxygen species. T…

  113. 162.

    Shao N, Wang J, Liu J, Zhang J, Zhang B, Sun X, Liu X. · 2026

  114. 163.

    Dhanekula AS, Harrison BR, Pharaoh G, Mattson-Hughes A, Tarantini S, Stuppard R, DeRoo SC, Burke CR, Hwang B, Pal JD, Mulligan MS, Marcinek DJ. · 2025 · PMID 41233677

    This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6 J mice received mitochondrial-targeted peptide elamipre…

  115. 164.

    Ji MH, Kreymerman A, Belle K, Ghiam BK, Muscat SR, Mahajan VB, Enns GM, Mercola M, Wood EH. · 2021 · PMID 34232272

    <h4>Translational relevance</h4>Mitochondria are viable therapeutic targets for a broad spectrum of ocular diseases.

  116. 165.

    Verbal F, Rubilar N, Marileo A, Fierro H, Ramirez-Molina O, Pinto-Leon A, Yevénes G, Fuentealba J, Panes-Fernández J.

  117. 166.

    Jurja S, Negreanu-Pirjol T, Mehedinți MC, Hincu MA, Lepadatu AC, Negreanu-Pirjol BS. · 2025 · PMID 41375126

    Cerebral ischemia represents a major mortality and disability cause; oxidative stress is the main intensifier mechanism of excitotoxicity, neuroinflammation, blood-brain barrier failure, and neuronal loss; under these circumstances, firm, mechanism-anchored neuroprotection is an absolute necessity. The work includes a exhaustive, PRISMA (Preferred reporting items for systematic review and meta-analysis)-adherent presentation of the effects of antioxidant peptides and small molecules on tissues,…

  118. 167.

    Liu M, Jin Y. · 2026 · PMID 41923743

    Heart failure (HF) is steadily increasing in prevalence and poses a major global health challenge, with substantial medical and economic burdens. HF represents the terminal stage of diverse cardiac disorders and is characterized by poor prognosis despite the availability of conventional pharmacological treatments, underscoring the urgent need for novel therapeutic approaches. Accumulating evidence highlights a strong association between HF and mitochondrial dysfunction, of which dysregulated mit…

  119. 168.

    Shen Y, Ye XM, Li PY, Chen SL. · 2026 · PMID 42057900

    Sepsis-associated encephalopathy (SAE) is a devastating neurological complication of sepsis, leading to diffuse brain dysfunction, long-term cognitive deficits, and increased mortality. Its pathogenesis is complex, with mitochondrial dysfunction and neuroinflammation emerging as central, interconnected drivers. This review systematically elucidates the pathogenic crosstalk between these two processes. We detail how dysregulated mitochondrial dynamics (e.g., Drp1-mediated fission), impaired bioge…

  120. 169.

    Capece U, Nilo D, Morciano C, Nilo R, Spiezia S, Sircana MC, Russo V, Perrone MA, Bonfrate L, Acierno C, Sasso FC, Caturano A. · 2026 · PMID 41897405

    Diabetic cardiomyopathy (DCM) is a distinct myocardial disorder that develops independently of coronary artery disease and hypertension and represents a major contributor to heart failure in patients with diabetes. Beyond hemodynamic alterations, DCM is driven by complex molecular mechanisms involving metabolic dysregulation, mitochondrial dysfunction, inflammation, and fibrotic remodeling. Increasing evidence identifies oxidative stress as a central integrative process linking these pathogenic…

  121. 170.

    Zaroon Z, D'Ambrosio C, de Nigris F. · 2026 · PMID 41594660

    Acute kidney injury (AKI) remains a major clinical challenge, with high morbidity and limited therapeutic options. In recent years, mitochondria have gained considerable attention as key regulators of the metabolic and immune responses during renal injury. Beyond their classical role in ATP production, mitochondria participate directly in inflammatory signaling, releasing mitochondrial DNA and other DAMPs that activate pathways such as TLR9, cGAS-STING, and the NLRP3 inflammasome. At the same ti…

  122. 171.

    Squillace A, Fernando MG, Sullivan K, Kiat H, Martins RN. · 2026 · PMID 41596136

    Mitochondrial dysfunction and oxidative stress are crucial contributors to the pathogenesis of Alzheimer's disease (AD) and dementia exhibiting cognitive decline at the early stage of neurodegeneration. Natural vitamin antioxidants (NVAs) and novel mitochondria-targeted antioxidants (MTAs) are proposed as potential therapeutics though conclusive evidence is lacking. Objectives were to examine in vivo evidence on NVAs and MTAs for preventing and/or treating cognitive decline leading to dementia,…

  123. 172.

    Mweene BC, Hatwiko H, Povia JP, Masenga SK. · 2025 · PMID 41007357

    Hypertensive heart disease (HHD) is characterized by pressure overload-induced cardiac remodeling, in which mitochondrial dysfunction has emerged as a central contributor to pathophysiology. Mitochondria occupy roughly one-third of the volume of a cardiomyocyte and serve as the primary source of ATP for the constantly active heart, while also regulating calcium homeostasis, redox balance, and apoptotic signaling. Chronic hypertension imposes energetic and oxidative stress on cardiomyocytes, disr…

  124. 173.

    Zhu M, Song L, Wei Y, Hong F, Lu Y, Ji J, Yan Y. · 2025 · PMID 40800174

    <h4>Background</h4>Mitochondrial-targeting anti-oxidant Szeto-Schiller 31 (SS-31) can ease lung injury in several diseases, but whether SS-31 can ameliorate acute lung injury (ALI) in neonatal acute respiratory distress syndrome (ARDS) is unclear. The objective of this study is to explore the efficacy of SS-31 against ALI and the associated molecular mechanisms.<h4>Methods</h4>Thioredoxin-interacting protein (TXNIP) was found to be a hub gene for ARDS by bioinformatics analysis. Using the Search…

  125. 174.

    Renke G, Chinellato L. · 2026 · PMID 42123471

    Therapeutic peptides are short chains of amino acids used to treat metabolic and endocrine conditions such as obesity and type 2 diabetes. While several peptide drugs have undergone rigorous approval processes that evaluate both safety and efficacy, novel, unapproved compounds have emerged and are rapidly expanding into preventive medicine and performance enhancement. Our objective is to present the effects, clinical applications, safety profiles, and regulatory status of prominent peptides used…

  126. 175.

    Badejogbin OC, Agunloye MO, Chijioke-Agu OE, Olubiyi MV, Olugbuyiro SO, Soetan OA, Bamgbose OA, Olaleye TO. · 2026 · PMID 41608077

    <h4>Background</h4>Polycystic ovary syndrome (PCOS) is a common endocrine disorder that significantly increases cardiovascular disease (CVD) risk in women. While insulin resistance and dyslipidemia are established contributors, growing evidence highlights mitochondrial dysfunction and chronic low-grade inflammation as central drivers of cardiovascular pathology in PCOS.<h4>Objective</h4>This narrative review synthesizes current evidence on how mitochondrial dysfunction and inflammation interact…

  127. 176.

    Najafi A, Sharifi SD, Farhadi R, Bapir SH. · 2025 · PMID 40604246

    Cryopreservation of rooster sperm is a vital technique in avian reproductive management; however, it is often hindered by oxidative stress induced by reactive oxygen species (ROS) that negatively impact sperm quality during the freezing-thawing process. The present study aimed to investigate the impact of elamipretide, a mitochondria-targeted peptide, on sperm quality post-thaw. Sperm samples from 32-week-old broiler breeder roosters were cryopreserved using a Lake extender buffer with glycerol…

  128. 177.

    Elmorsy EA, Amer MM, Hamad RS, Abdel-Hamed MR, Farrag AA, Alorini M, Khodeir MM, Ali MAM, Alhowail AH, Mohamed EA, Alsalloom AA, Alsaykhan H, Alsoqih NS, Ata HS, Sameh A, Chaudhary AA, Saber S. · 2026 · PMID 41934921

    Acute lung injury (ALI) is defined by disruption of alveolar-capillary architecture, inflammatory remodeling of the parenchyma, and barrier dysfunction. Mitochondrial structural damage can promote release of mitochondrial danger signals that engage cytosolic DNA sensing and amplify tissue injury. Here, we tested whether dual targeting of mitochondrial structure-function (elamipretide, ELM) and STING signaling (H151) preserves lung tissue organization. At 24 h post intratracheal lipopolysaccharid…

  129. 178.

    Meng L, Wu G. · 2023 · PMID 37435377

    Mitochondrial disorders are observed in various human diseases, including rare genetic disorders and complex acquired pathologies. Recent advances in molecular biological techniques have dramatically expanded the understanding of multiple pathomechanisms involving mitochondrial disorders. However, the therapeutic methods for mitochondrial disorders are limited. For this reason, there is increasing interest in identifying safe and effective strategies to mitigate mitochondrial impairments. Small-…

  130. 179.

    Masenga SK, Povia JP, Mweene BC, McMillian R, Albritton C, Gillyard T, Afolabi J, Garza Lopez E, Rodriguez B, Crabtree A, AshShareef S, Mungai M, Le H, Marshall A, Katti P, Neikirk K, Kirabo A, Hinton A. · 2025 · PMID 41551943

    Salt sensitivity of blood pressure is prevalent in the aging population, characterized by an exaggerated hypertensive response to dietary sodium intake. Emerging evidence implicates mitochondrial dysfunction as a central contributor to salt sensitivity of blood pressure with mechanistic involvement of oxidative stress, endoplasmic reticulum stress, disrupted mitochondrial-endoplasmic reticulum contacts, and impaired autophagy. This review explores the interplay between aging, mitochondrial dysfu…

  131. 180.

    Qiu Y, Chang S, Zeng Y, Wang X. · 2025 · PMID 41148836

    Cardiovascular diseases (CVDs) remain the leading cause of morbidity and mortality worldwide and is attributed to complex pathophysiological mechanisms that surpass the traditional risk factors. Emerging evidence indicates that mitochondrial dysfunction plays a central role in CVD progression, linking impaired bioenergetics, oxidative stress imbalance, and defective mitochondrial quality control to endothelial dysfunction, myocardial injury, and adverse cardiac remodeling. However, the mechanist…

  132. 181.

    Hou Y, Yang X, Zhao T, Guo Y, Shi J. · 2026 · PMID 41561138

    Degenerative joint diseases, such as osteoarthritis (OA), intervertebral disc degeneration (IVDD) and rheumatoid arthritis (RA), cause pain and disability worldwide. Globally, OA affects >500 million individuals, IVDD affects 40-60% of adults and RA affects 0.5-1% of the global population. Current treatments (such as non-steroidal anti-inflammatory drugs and corticosteroids for OA, conservative management and spinal surgery for IVDD, and disease-modifying anti-rheumatic drugs/biologics for RA) f…

  133. 182.

    Lu T, Chen SQ, Li SH, Li SP, Wu YX, Pang QF, Chen D. · 2026 · PMID 42074001

    Mitochondrial dysfunction plays a central role in the pathogenesis of bronchopulmonary dysplasia (BPD). Solute carrier family 25 member 28 (SLC25A28) is an iron transporter located in the inner mitochondrial membrane. In this study, we aimed to explore the role and underlying molecular mechanisms of SLC25A28 in BPD. Hyperoxia (85% O<sub>2</sub>) was used to establish a neonatal murine model of BPD, and mouse lung epithelial cells (MLE-12 cells) were used in vitro. SLC25A28 expression and activit…

  134. 183.

    Marjoram L · Journal of developmental biology · 2026 · PMID 42924728

    The 2026 Barth Syndrome International Scientific, Medical & Family Conference was held at the Hyatt Regency Coconut Point, Bonita Springs, Florida, USA, from 19th to 25th July 2026 with scientific programming beginning 22nd July. This biennial event assembled researchers, clinicians, and affected community members for its first gathering since the U.S. FDA granted accelerated approval to elamipretide (Forzinity™; Mighty Therapeutics), the first therapy for Barth syndrome and first ever mitochond…

  135. 184.

    Zhao Y, Yan H, Wang L, Lei Y, et al. · Frontiers in pharmacology · 2026 · PMID 42898512

    Premature ovarian failure (POF) is a complex endocrine disorder that severely impairs female fertility. Cisplatin, a commonly used chemotherapeutic agent, has been identified as a major risk factor for POF in young women. This study aimed to investigate the protective effects and underlying mechanisms of the mitochondria-targeted peptide elamipretide (SS31) in a cisplatin-induced mouse model of POF. POF was established via intraperitoneal cisplatin (2 mg/kg, 7 days), followed by SS31 treatment (…

  136. 185.

    Zhang HL, Wang Y, Wang C, Guo X, et al. · Aging cell · 2026 · PMID 42827331

    Aging represents a major contributor to the deterioration of female fertility, with oocyte quality being the central determinant of ovarian aging, a key factor underlying infertility. Although several natural compounds with anti-aging activity have been documented, highly effective strategies to reverse ovarian aging remain elusive. Here, we report that the peptide elamipretide preserves ovarian function and sustains female fertility during maternal aging. We found that elamipretide administrati…

  137. 186.

    Mei R, Zhang R, Li Z, Luo J, et al. · Journal of gastroenterology and hepatology · 2026 · PMID 42638278

    Mitochondrial dysfunction in macrophages drives pro-inflammatory M1 polarization in ulcerative colitis (UC). We developed a colon-targeted, mitochondria-directed nanoplatform (KSF@SS31@S100Ns) to restore mitochondrial fitness and alleviate UC. Kaempferol-loaded silk fibroin (SF) nanoparticles were conjugated with SS-31 peptide and coated with pH-sensitive Eudragit S100. Physicochemical properties, release profile, and uptake were characterized. Mitochondrial function, macrophage polarization, an…

  138. 187.

    Lu L, Su Y, Zheng L, Fan Z, et al. · ACS applied materials & interfaces · 2026 · PMID 42709510

    Despite decades of intensive investigation, rheumatoid arthritis (RA) remains a therapeutic challenge, primarily attributed to its intricate pathological microenvironment and poorly elucidated etiology. However, mitochondrial dysfunction and abnormal activation of the cGAS-STING signaling pathway play a key role in RA. Herein, we report mitochondria targeted biomimetic nanovesicles (SS31-CB@MM-FNVs/CLT) for the targeted therapy of RA. SS31-CB@MM-FNVs/CLT is constructed by macrophage membrane fus…

  139. 188.

    Villatore A, Ehle EA, Chelko SP · Trends in pharmacological sciences · 2026 · PMID 42448476

  140. 189.

    Xiao D, Cui X, Ali S, Li C, et al. · Physiological research · 2026 · PMID 42708867

    Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major cause of cirrhosis, liver cancer, and cardiovascular disease. Early mitochondrial dysfunction drives lipid imbalance, inflammation, and fibrosis. Given the lack of approved pharmacological treatments, this study compares the mitochondria-targeted agents MitoQ and SS-31 for their effects on mitochondrial function, oxidative stress, apoptosis, and inflammation in aged, nutritionally stressed mice with MASLD. Aged female C5…

  141. 190.

    Vahle B, Weidner S, Tomalka A, Schauer A, et al. · Circulation. Heart failure · 2026 · PMID 42290373

    Exercise intolerance, promoted by skeletal muscle- and mitochondrial dysfunction, has been identified as a therapeutic target in heart failure with preserved ejection fraction (HFpEF). In the context of mitochondrial dysfunction, altered cardiolipin integrity has been reported in the myocardium of HFpEF, suggesting Elamipretide, a cardiolipin stabilizing agent, as potential therapeutic approach. The present study investigated cardiolipin dysregulation in the skeletal muscle of HFpEF rats and ana…

  142. 191.

    Xie L, Wu J, Fan J, Krager KJ, et al. · Journal of radiation research · 2026 · PMID 42456009

    Exposure to ionizing radiation, such as from radiation therapy or accidental radiation exposure can have adverse effects on the heart. While radiation injury in the heart may include cardiomyocyte senescence, there are no available strategies to prevent this phenomenon. This study evaluated the effects of the mitochondrial-targeted peptide SS-31 (elamipretide) on radiation-induced cell senescence in cardiomyoblast H9C2 cells and human induced pluripotent stem cell derived cardiomyocytes (hiPSC-C…

  143. 192.

    Yang Q, Zhang Y, Liu P, Yan Z, et al. · Neurochemical research · 2026 · PMID 42443448

    Ischemic stroke is a severe cerebrovascular disorder characterized by a cascade of pathological processes, including neuroinflammation and apoptosis. These processes lead to high mortality rates and long-term disabilities, imposing substantial socioeconomic burdens. Although reperfusion therapies have improved patient outcomes, many remain ineligible due to narrow therapeutic windows or clinical contraindications. Consequently, developing novel neuroprotective strategies is of significant clinic…

  144. 193.

    Wen Y, Zhao Z, Zheng X, Zhao Y, et al. · Nano letters · 2026 · PMID 42358073

    Ischemia-reperfusion injury (IRI) remains a major cause of graft dysfunction following kidney transplantation, driven in large part by mitochondrial oxidative stress and subsequent apoptotic cell death. Elamipretide (SS31), a mitochondria-targeted tetrapeptide, shows robust renoprotection in preclinical models but is constrained by rapid renal elimination and limited pharmacokinetic exposure. Here, we prepared multiarm PEG-SS31 conjugates with controlled arm number and total PEG molecular weight…

  145. 194.

    Flavin B, Vernon HJ, Todd Cade W, Contreras Z, et al. · Journal of managed care & specialty pharmacy · 2026 · PMID 42359884

    Barth syndrome is an ultrarare, complex, multisystem, X-linked metabolic and neuromuscular disease, which poses significant and wide-ranging burden to patients and caregivers. Pharmacologic management focuses on treatment of disease manifestations and prevention of secondary complications. Elamipretide, the first treatment indicated specifically for improving muscle strength in Barth syndrome, was approved in 2025 via accelerated approval warranting guidance for payers. To discuss managed care c…

  146. 195.

    Fan J, Wu J, Yan S, Li S, et al. · Biology · 2026 · PMID 42450582

    Doxorubicin (DOX), an effective chemotherapeutic agent for many types of cancer, is known for significant cardiotoxic side effects, which largely limit its clinical usage. A 3 h treatment of cardiomyoblast H9C2 cells with a low concentration of DOX (100 nM) can induce senescence-associated β-galactosidase (SA β-gal) staining, a gold standard of cell senescence. In the current study, we comprehensively characterized the phenotype of the DOX-induced senescent cardiomyocytes for the first time. Est…

  147. 196.

    Stefaniak E, Cui B, Yan X, Sun K, et al. · Chemical biology & drug design · 2026 · PMID 42219795

    Membrane binding and aggregation properties of α-synuclein are closely associated with Parkinson's disease and a class of related syndromes named as synucleinopathy. This study explored the potential of SS-31 (Elamipretide), a therapeutic tetrapeptide with alternating cationic and aromatic residues and known properties of mitochondrial inner membrane binding and oxidative stress reduction, in modulating α-synuclein interaction with the lipid membranes and mitigating the impairment of mitochondri…

  148. 197.

    Cui J, Han H, Man Z, Gao Y, Liu J, Li R, Zhang Y, Lu S, An Z, Chen L, Pang K, Zhao Z, Lei P, Wang G, Zhang P, Li W. · 2026 · PMID 42786626

    Osteoarthritis is a prevalent degenerative joint disorder characterized by chronic inflammation and oxidative stress, with current treatments offering limited efficacy in halting disease progression. A central pathogenic driver is the mitochondrial overproduction of reactive oxygen species (ROS), which induces cellular components damage, propagates inflammatory signaling, and accelerates cellular senescence. Although some natural enzymes can neutralize ROS, their therapeutic applications are sev…

  149. 198.

    Zhang Z, Du Q, Zhu Z, Zhu Z, He J, Xin Z, Deng J. · 2026 · PMID 42586485

    Precise mitochondrial targeting in chondrocytes is essential for interrupting the vicious cycle of oxidative stress and cartilage degeneration in osteoarthritis (OA). Here, we develop a biomimetic nanoplatform (CM@SS31-Se) with dual targeting capability. This system comprises selenium nanoparticles with glutathione peroxidase mimetic activity as the antioxidant core, SS31 peptide for mitochondrial homing, and chondrocyte membrane coating for homotypic recognition. Following intra-articular injec…

  150. 199.

    Cui N, Zhang RX, Yang Q, Ren Y, Jia J, Wang X, Liu X, He Y. · 2026 · PMID 42774068

    <h4>Purpose</h4>Glaucoma is a group of neurodegenerative diseases characterized by progressive loss of retinal ganglion cells (RGCs) and optic nerve fibers. Mitochondrial dynamics contribute to the maintenance of neuronal homeostasis, and abnormalities can lead to the development of glaucoma. SS31 is a mitochondria-targeting short peptide that has been found to protect mitochondrial function and thereby protect damaged retina-associated cells. The aim of this study is to investigate whether SS31…

Preprints (not yet peer-reviewed)

5
  1. 200.

    Mendias CL, Awan TM. · 2026

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  2. 201.

    Mendias CL, Awan TM. · 2025

    Peptides are short chains of amino acids with a unique pharmacological niche between small-molecule drugs and large proteins. Their use in sports medicine is rapidly expanding, driven by patient demand for accelerated injury recovery and performance enhancement. While numerous peptide drugs have undergone a rigorous approval process that evaluates both safety and efficacy, a parallel "gray market" of unapproved compounds has emerged, operating largely outside regulatory oversight. Our objective…

  3. 202.

    Dhanekula AS, Harrison BR, Pharaoh G, Mattson-Hughes A, Tarantini S, Stuppard R, DeRoo SC, Burke CR, Hwang B, Pal JD, Mulligan MS, Marcinek DJ. · 2025

    This study investigated the role of mitochondrial function in aortic aging. As the aorta ages, it becomes stiffer and less compliant, increasing the risk of aneurysmal disease, hypertension, and diastolic dysfunction. Given the role of mitochondrial dysfunction in non-age related aortopathies and as a hallmark of aging, we investigated its contribution to the aging aorta. Both male and female young (5-6 month) and aged (24-25 month) C57Bl/6J mice received mitochondrial-targeted peptide elamipret…

  4. 203.

    Ivchuk V. · 2026

    This study examines cardiolipin (CL) as a unique mitochondrial phospholipid that not only fulfills structural functions within the inner mitochondrial membrane but also acts as a programmable signaling hub. Current perspectives on CL biosynthesis, remodeling, and oxidative modifications are analyzed, alongside its role in stabilizing cristae, respiratory supercomplexes, mitophagy, apoptosis, and innate immunity. Based on the concept of CL-dependent signaling platforms – specifically the catalyti…

  5. 204.

    Vu J, Wagg CS, Holody C, Wong A, Baidwan T, Lo M, Khodabocus I, Liu SN, Macala K, Dufour A, Ussher J, Lemieux H, Lopaschuk GD, Bourque SL. · 2026

    Sepsis-induced cardiac dysfunction (SICD) occurs in nearly half of septic patients, is associated with increased mortality, and lacks targeted therapy. Emerging evidence implicates impaired mitochondrial function and metabolic inflexibility as central contributors to myocardial depression. Here, we characterized SICD in a murine model of polymicrobial sepsis and evaluated the therapeutic potential of the cardiolipin-stabilizing peptide elamipretide (Ela). Sepsis induced marked impairments in car…

Case Reports

2
  1. 205.

    Jacob N, Schecter D, Marshall M, Bansal N, et al. · Molecular genetics and metabolism · 2025 · PMID 40816230

    Barth syndrome is an exceedingly rare and potentially fatal X-linked mitochondrial disease arising from pathogenic variants in TAFAZZIN (TAZ), leading to defects in mature cardiolipin synthesis and its integration into the mitochondrial inner mitochondrial membrane. Clinical features that may be severe include cardiomyopathy, cyclic neutropenia, skeletal myopathy, and growth delay. Currently, no FDA-approved therapies exist. Elamipretide (ELAM) has been shown to stabilize cardiolipin and improve…

  2. 206.

    Amedro P, Andrianoely M, Gohier P, Leroux J, et al. · Orphanet journal of rare diseases · 2026 · PMID 42415111

    Barth syndrome (BTHS) is a rare X-linked mitochondrial disorder characterized by cardiomyopathy, neutropenia, and skeletal myopathy. Elamipretide is a mitochondria-targeting peptide that stabilizes cardiolipin and improves mitochondrial function. While use of this treatment in infants with BTHS has been reported in the United States, no cases have been described outside the US or in older children. We report the first case of a preschool-aged child with genetically confirmed BTHS and advanced he…

Curated sources on file

17
  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.

Continue reading